Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
JNJ Stock News and Mentions of Johnson & Johnson Stocktwits
Updated: April 26, 2024 (09:55)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Johnson & Johnson Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Johnson & Johnson (JNJ).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Johnson & Johnson stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Johnson & Johnson (JNJ)
April 26, 2024 (12:13) / "Zacks Commentary" (by Nalak Das)
5 Stocks in Focus on Their Recent Dividend Hike
Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.
In Article Trend: Somewhat-Bullish
April 26, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024 - Cidara Therapeutics ( NASDAQ:CDTX )
SAN DIEGO, April 26, 2024 ( GLOBE NEWSWIRE ) -- Cidara Therapeutics, Inc.
In Article Trend: Somewhat-Bullish
April 25, 2024 (18:27) / "PR Newswire" (by BioNJ)
BioNJ Announces Lineup for BioPartnering Conference
TRENTON, N.J., April 25, 2024 /PRNewswire/ -- BioNJ is pleased to host its 14th Annual BioPartnering Conference on Tuesday, May 14, at the Liberty Science Center in Jersey City. Sponsored by J.P.
In Article Trend: Bullish
April 25, 2024 (15:59) / "Benzinga" (by Gary Brode)
Monthly Depth Report: The Blind Leading The Confused - Shockwave Medical ( NASDAQ:SWAV )
One of the best experiences I've had in my investment career was being partner and co portfolio manager with Raji Khabbaz. He's a fantastic stock-picker and the two of us spent the better part of a decade discussing and debating investment ideas.
In Article Trend: Neutral
April 25, 2024 (13:15) / "Motley Fool" (by Adam Spatacco)
Here Are My Top 5 Dividend Kings to Buy Right Now
Dividend Kings are hard to come by, but these five stocks offer investors some great passive income opportunities.
In Article Trend: Somewhat-Bullish
April 25, 2024 (09:37) / "Motley Fool" (by David Jagielski)
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
In Article Trend: Somewhat-Bullish
April 25, 2024 (06:40) / "GlobeNewswire" (by VIRTUALWARE 2007 SA)
Pre-Investor Call Presentation available to shareholders
Investors can access and view today's presentation materials by following this link: Headquartered in Bilbao, Spain, Virtualware is a global pioneer in developing virtual reality solutions for large industrial, educational, and healthcare conglomerates.
In Article Trend: Somewhat-Bullish
April 24, 2024 (22:47) / "Investing News Network" (by Investing News Network)
Investing in Cardiovascular MedTech Companies
Efforts to address the core risk factors associated with cardiovascular diseases are coinciding with recent innovations in medical technology, which have been critical in not only preventing and managing them but also increasing the survival rate.
In Article Trend: Bullish
April 24, 2024 (20:40) / "GlobeNewswire" (by Nanobiotix S.A.)
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
Conference call and webcast scheduled for April 25, 2024 at 8:00 A.M. EDT / 2:00 P.M. CEST ...
In Article Trend: Neutral
April 24, 2024 (19:53) / "CNBC" (by Kevin Stankiewicz)
Here's a rapid-fire update on all 33 portfolio stocks including our tech giants reporting this week
During the Investing Club's Monthly Meeting on Wednesday, Jim Cramer offered his updated thinking on the stocks in the portfolio.
In Article Trend: Neutral
April 24, 2024 (17:58) / "Zacks Commentary" (by Zacks Equity Research)
Vanda ( VNDA ) to Report Q1 Earnings: What's in the Cards?
On Vanda's (VNDA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed drugs and certain pipeline and regulatory updates.
In Article Trend: Neutral
April 24, 2024 (13:19) / "Zacks Commentary" (by Ahan Chakraborty)
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.
In Article Trend: Somewhat-Bullish
April 24, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson are part of the Zacks top Analyst Blog.
In Article Trend: Neutral
April 24, 2024 (10:10) / "Motley Fool" (by Keith Speights)
These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years
These stocks kept members of Congress especially busy.
In Article Trend: Somewhat-Bullish
April 24, 2024 (09:25) / "Motley Fool" (by Justin Pope)
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Buying great stocks when they're on sale is a lucrative long-term strategy.
In Article Trend: Somewhat-Bullish
April 24, 2024 (08:00) / "GlobeNewswire" (by Alvotech)
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® ( golimumab )
Alvotech ( NASDAQ: ALVO ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today positive topline results from a confirmatory clinical study for AVT05, Alvotech's proposed biosimilar to Simponi® and Simponi Aria® ...
In Article Trend: Neutral
April 23, 2024 (13:20) / "Investors Business Daily" (by Investor's Business Daily)
The No. 1 Biotech Stock Just Launched Higher - Here's Why
Biotech Stock Neurocrine Launches Higher On A Depression Treatment Win Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 23, 2024 (12:42) / "Zacks Commentary" (by Ritujay Ghosh)
4 Stocks to Watch on Their Recent Dividend Hikes
Stocks like KB Home (KBH), Interactive Brokers Group, Inc. (IBKR), QUALCOMM Incorporated (QCOM) and Johnson & Johnson (JNJ) recently hiked dividends.
In Article Trend: Neutral
April 22, 2024 (21:33) / "Benzinga" (by Globe Newswire)
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
In Article Trend: Somewhat-Bullish
April 22, 2024 (15:53) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation ( Nasdaq - MCBC ) , Shockwave Medical, Inc. ( Nasdaq - SWAV ) , Apartment Income REIT Corp. ( NYSE - AIRC ) , Model N, Inc. ( NYSE - MODN )
BALA CYNWYD, Pa., April 22, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
April 22, 2024 (15:10) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WIRE, ABIO, SWAV, MODN - Model N ( NYSE:MODN ) , ARCA biopharma ( NASDAQ:ABIO )
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
In Article Trend: Neutral
April 22, 2024 (13:47) / "Benzinga" (by Globe Newswire)
Kuehn Law Encourages WIRE, ABIO, MODN, and SWAV Investors to Contact Law Firm - Model N ( NYSE:MODN ) , ARCA biopharma ( NASDAQ:ABIO )
NEW YORK, April 22, 2024 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
In Article Trend: Somewhat-Bullish
April 22, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In Article Trend: Somewhat-Bullish
April 22, 2024 (10:10) / "Business Insider" (by George Glover)
Stock market today: US futures climb as traders await crucial 'Magnificent 7' earnings reports
Samp;P 500 futures were up 0.5% shortly before 6 a.m. ET, while Nasdaq 100 futures had climbed 0.6%. The Dow Jones Industrial Average was on pace to add 165 points.
In Article Trend: Somewhat-Bullish
April 22, 2024 (10:10) / "Business Insider" (by George Glover)
Stock market today: US futures climb as traders await crucial 'Magnificent 7' earnings reports
Stock market today: US futures climb ahead of Magnificent 7 earnings - Business Insider ...
In Article Trend: Neutral
April 20, 2024 (19:25) / "Forbes" (by Cailey Gleeson)
Court Orders Johnson & Johnson And Kenvue To Pay $45 Million In Talcum Baby Powder Lawsuit
An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based baby powder led to the death of a relative diagnosed with a fatal cancer linked to asbestos exposure, the company's latest legal issue ...
In Article Trend: Somewhat-Bearish
April 20, 2024 (13:36) / "Forbes" (by Michael Foster)
Don't Let Media-Driven Fears Keep You From These 7%+ Dividends
It's starting again-the media has its hooks into a new story to scare investors, in yet another effort to gain attention. The upshot is that we've now got a very nice opportunity to pick up a special kind of closed-end fund ( CEF ) that yields 7%+ and does something unusual to limit downside.
In Article Trend: Neutral
April 19, 2024 (22:12) / "PR Newswire"
Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... - PR Newswire
Endoscopy Devices Market size is set to grow by USD 14.24 billion from 2024-2028, advances in endoscopy ... PR ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (16:51) / "Investors Business Daily" (by IBD STAFF)
Stock Market Shows Bearish Action: Weekly Review
Stock Market Sells Off. Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
)
April 19, 2024 (14:54) / "Business Standard" (by Reuters)
WHO says wider warning about contaminated J&J cough syrup 'likely'
The World Health Organization is likely to issue a wider warning about contaminated Johnson and Johnson-made children's cough syrup found in Nigeria last week, it said in an email. Nigeria's regulator recalled a batch of Benylin syrup last Wednesday, having found a high level of diethylene glycol ...
In Article Trend: Neutral
April 19, 2024 (14:40) / "Business Insider" (by Shriya Bhattacharya)
A creator made 5 figures with a dating podcast and quit her job to focus on her side hustle full-time. She breaks down her income from brand deals, sponsored events, and more.
How Much a Creator Makes in a Year From Events, Brand Deals, TikTok - Business Insider ...
In Article Trend: Neutral
April 19, 2024 (14:17) / "Benzinga" (by Vandana Singh)
Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert - Johnson & Johnson ( NYSE:JNJ )
The World Health Organization ( WHO ) is poised to issue a broader alert regarding contaminated children's cough syrup produced by Johnson and Johnson JNJ in response to the discovery of tainted batches in Nigeria.
In Article Trend: Neutral
April 19, 2024 (13:00) / "GlobeNewswire" (by White River Bancshares)
White River Bancshares Co. Earns $509,000, or $0.51 Per Diluted Share, in First Quarter 2024; Highlighted by Higher Net Interest Income and Double Digit Loan and Deposit Growth Year-Over-Year
FAYETTEVILLE, Ark., April 19, 2024 ( GLOBE NEWSWIRE ) -- White River Bancshares Company ( OTCQX: WRIV ) , ( the "Company" ) the holding company for Signature Bank of Arkansas ( the "Bank" ) , today reported net income of $509,000, or $0.51 per diluted share, in the first quarter of 2024, ...
In Article Trend: Somewhat-Bullish
April 19, 2024 (10:00) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron
NVIDIA, Alphabet, Johnson & Johnson, Broadridge Financial and Textron are included in this Analyst Blog.
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:22) / "Zacks Commentary" (by Sheraz Mian)
Top Stock Reports for NVIDIA, Alphabet & Johnson & Johnson
Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Alphabet Inc. (GOOGL) and Johnson & Johnson (JNJ).
In Article Trend: Somewhat-Bullish
April 18, 2024 (15:09) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.
In Article Trend: Somewhat-Bullish
April 18, 2024 (14:32) / "Benzinga" (by Benzinga Insights)
Unpacking the Latest Options Trading Trends in Johnson & Johnson - Johnson & Johnson ( NYSE:JNJ )
Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 9 unusual trades. Delving into the details, we found 44% of traders were bullish, while 55% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
April 18, 2024 (12:37) / "Investors Business Daily" (by Investor's Business Daily)
Home Depot Primed For Bounce; How To Capitalize With Options
Home Depot Primed For Bounce. How To Capitalize With Options Investor's Business Daily ...
In Article Trend: Neutral
April 17, 2024 (19:37) / "Benzinga" (by Vandana Singh)
Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About Future - Johnson & Johnson ( NYSE:JNJ )
On Tuesday, Johnson & Johnson JNJ reported first-quarter adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64. The pharma giant reported sales of $21.38 billion, up 2.3% year over year, almost in line with the consensus of $21.39 billion.
In Article Trend: Somewhat-Bullish
April 17, 2024 (17:51) / "Benzinga" (by Avi Kapoor)
Johnson & Johnson Analysts Cut Their Forecasts After Q1 Results - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ reported better-than-expected first-quarter earnings on Tuesday. The company posted adjusted EPS of $2.71, up 12.4% year over year, beating the consensus of $2.64.
In Article Trend: Neutral
April 17, 2024 (14:00) / "Zacks Commentary" (by Sweta Killa)
JNJ Beats Q1 Earnings Estimates, Misses on Sales: ETFs in Focus
Johnson & Johnson (JNJ) continued with its long streak of earnings beat but lagged revenue estimates.
In Article Trend: Somewhat-Bullish
April 17, 2024 (13:17) / "Zacks Commentary" (by Zacks Equity Research)
April 17, 2024 (13:05) / "Benzinga" (by Globe Newswire)
TRC Amends Its Tender Offer for Johnson & Johnson
TORONTO, April 17, 2024 ( GLOBE NEWSWIRE ) -- TRC Capital Investment Corporation ( TRC ) announced today that based on current market conditions, TRC has amended the terms of its tender offer for up to 1,000,000 common shares of Johnson & Johnson ( the Company ) and has decreased the offer price ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (12:21) / "Benzinga" (by Avi Kapoor)
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Visa ( NYSE:V )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut the price target for Unity Biotechnology, Inc. UBX from $10 to $8.
In Article Trend: Neutral
April 17, 2024 (10:30) / "Forbes" (by Alexandra S. Levine)
TikTok Mishandled The Data Of Hundreds Of Top American Advertisers
Sensitive business information from advertisers like Amazon, Disney and the New York Times was widely available to ByteDance staff across the U.S. and China, Forbes has learned. TikTok, which is fighting a ban over its handling of data, declined to comment.
In Article Trend: Neutral
April 17, 2024 (03:38) / "The Financial Express" (by BrandWagon Online)
IAA and ISA to host 'Retrospect & Prospects' event in Mumbai with industry leaders
The India Chapter of the International Advertising Association ( IAA ) and The Indian Society of Advertisers ( ISA ) will host an event titled 'Retrospect & Prospects' featuring Manish Anandani, managing director - India, Kenvue ( formerly Johnson & Johnson ) , on April 24th in Mumbai.
In Article Trend: Bullish
April 16, 2024 (21:45) / "Motley Fool" (by Eric Volkman)
Why Johnson & Johnson Stock Got Tossed by the Market Today
A mixed quarter and narrowed guidance didn't really please investors.
In Article Trend: Neutral
April 16, 2024 (21:30) / "GlobeNewswire" (by Alvotech)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ ( ustekinumab-aekn ) , biosimilar to Stelara® ( ustekinumab )
REYKJAVIK, ICELAND & PARSIPPANY, NJ - Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved SELARSDI ( ustekinumab-aekn ) injection for ...
In Article Trend: Neutral
April 16, 2024 (21:30) / "GlobeNewswire" (by Alvotech)
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ ( ustekinumab-aekn ) , biosimilar to Stelara® ( ustekinumab )
REYKJAVIK, Iceland and PARSIPPANY, N.J., April 16, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO ) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. ( NYSE and TASE: TEVA ) , today announced that the U.S. Food and Drug Administration ( FDA ) has approved ...
In Article Trend: Neutral
April 16, 2024 (20:11) / "Kiplinger" (by Karee Venema)
Stock Market Today: Stocks Stabilize After Powell's Rate-Cut Warning
Stocks struggled for direction Tuesday as investors took in the latest round of corporate earnings reports and a mid-afternoon speech from Fed Chair Jerome Powell. At the close, the S&P 500 ( -0.2% at 5,051 ) and the Nasdaq Composite ( -0.1% at 15,865 ) had made modest moves.
In Article Trend: Somewhat-Bullish
April 16, 2024 (17:30) / "Motley Fool" (by Motley Fool Transcribing)
Johnson & Johnson ( JNJ ) Q1 2024 Earnings Call Transcript
JNJ earnings call for the period ending March 31, 2024.
In Article Trend: Somewhat-Bullish
April 16, 2024 (15:49) / "Benzinga" (by Upwallstreet)
Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit Spinoff - Johnson & Johnson ( NYSE:JNJ )
On Tuesday, Johnson & Johnson JNJ delivered a rather mixed first quarter report. Adjusted earnings surpassed estimates as sales in its medical devices business surged, while revenue was almost in line with estimates.
In Article Trend: Neutral
April 16, 2024 (15:02) / "Zacks Commentary" (by Zacks Equity Research)
Building Permits Come in Lower Than Expected
New housing data has hit the tape this morning. Housing Starts for March came in -14.7% to 1.3 million seasonally adjusted, annualized units. The previous month's tally has been downwardly revised to 1.45 million from 1.52 million initially reported.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:53) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft
J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.
In Article Trend: Somewhat-Bullish
April 16, 2024 (14:37) / "Investors Business Daily" (by Investor's Business Daily)
Stocks Mixed With Dow In The Lead Lifted By UnitedHealth
Stock Market Today: Dow Jones, S&P 500 Rebound, UnitedHealth JumpsInvestor's Business Daily Investor's Business Daily ...
In Article Trend: Neutral
April 16, 2024 (14:26) / "Zacks Commentary" (by Mark Vickery)
Housing Numbers Shrink as Q1 Earnings Heat Up: BAC, JNJ, UNH
Both Housing Starts and Building Permits missed expectations, while BofA, J&J and UnitedHealth all beat on earnings.
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:59) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MCBC, SWAV, AIRC, MODN - Macatawa Bank ( NASDAQ:MCBC ) , Apartment Income REIT ( NYSE:AIRC )
NEW YORK, April 16, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
In Article Trend: Somewhat-Bullish
April 16, 2024 (13:47) / "Benzinga" (by Akanksha Bakshi)
Crypto Analyst Signals Bitcoin Correction Amid Stumbling Rally; Intel and Nvidia Unveil China-Focused Products, Adjust AI Chip Strategies Amid US Sanctions - Top Headlines Today While US Slept
Crypto Analyst Warns Bitcoin's Impending Correction As Rally Falters: 'We Are Bearish Risk Assets' Peter Schiff Challenges Bitcoin's $100K Prediction As Crypto-Linked Stocks Languish In Bear Zone: 'Sell Your Fool's Gold And Buy The Real Thing' Altcoin Bloodbath Incoming?
In Article Trend: Neutral
April 16, 2024 (13:13) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Macatawa Bank Corporation ( Nasdaq - MCBC ) , Shockwave Medical, Inc. ( Nasdaq - SWAV ) , Apartment Income REIT Corp. ( NYSE - AIRC ) , Model N, Inc. ( NYSE - MODN )
BALA CYNWYD, Pa., April 16, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
April 16, 2024 (12:57) / "Investors Business Daily" (by ALLISON GATLIN)
Health Care Bellwether J&J Misses Sales Views, But Profit Beats
Johnson & Johnson Stock Dips On Light Sales, But Earnings Beat Forecasts Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (12:25) / "Investors Business Daily" (by SCOTT LEHTONEN)
Futures Rebound Ahead Of Powell Comments
Stock Market Today: Dow Jones Tries To Rebound After Sharp Losses. Tesla Stock Extends Sell-Off Investor's Business Daily ...
In Article Trend: Neutral
)
April 16, 2024 (11:51) / "Business Standard" (by Reuters)
J&J Q1 revenue below expectations at $21.38 bn as Stelara sales disappoint
J&J now expects adjusted operating profit per share between $10.60 and $10.75 for 2024, compared with its previous forecast of $10.55 to $10.75. Photo: Bloomberg
In Article Trend: Neutral
April 16, 2024 (11:30) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Q1 Earnings Top Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 2.65% and 0.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Somewhat-Bullish
April 16, 2024 (10:24) / "CNBC" (by Annika Kim Constantino)
Johnson & Johnson tops quarterly profit estimates as medical device sales jump
The company is benefiting from a rebound in demand for nonurgent surgeries among older adults, who deferred those procedures during the Covid pandemic.
In Article Trend: Neutral
April 16, 2024 (10:24) / "GlobeNewswire" (by Genmab A/S)
Genmab Announces Net Sales of DARZALEX® ( daratumumab ) for First Quarter of 2024
Company Announcement ...
In Article Trend: Neutral
April 16, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Fidelity MSCI Health Care Index ETF ( FHLC ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (08:35) / "Barrons" (by Joe Woelfel)
UnitedHealth, J&J, Live Nation, DJT, Tesla, Bank of America, Morgan Stanley, and More Stock Market Movers
Live Nation, DJT, Tesla, UnitedHealth, J&J, BofA, Morgan Stanley, and More Market Movers ...
In Article Trend: Neutral
April 16, 2024 (06:34) / "Business Insider" (by Avi Kapoor)
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Johnson & Johnson Likely To Report Higher Q1 Earnings. Here Are The Recent Forecast Changes From Wall Street's ... - Markets Insider ...
In Article Trend: Neutral
April 16, 2024 (06:15) / "Benzinga" (by Avi Kapoor)
Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ is set to release earnings results for its first quarter before the opening bell on April 16, 2024. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.64 per share, up from $2.41 per share in the year-ago period.
In Article Trend: Neutral
April 16, 2024 (06:10) / "Benzinga" (by Avi Kapoor)
Bank of America, Morgan Stanley And 3 Stocks To Watch Heading Into Tuesday - Bank of America ( NYSE:BAC ) , Morgan Stanley ( NYSE:MS )
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Bank of America Corporation BAC to report quarterly earnings at 77 cents per share on revenue of $25.46 billion before the opening bell, ...
In Article Trend: Somewhat-Bullish
April 16, 2024 (06:09) / "Benzinga" (by Avi Kapoor)
Fear & Greed Index Moves To 'Fear' Zone; S&P 500 Down Over 1% - Bank of America ( NYSE:BAC ) , Goldman Sachs Gr ( NYSE:GS )
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index moving to the "Fear" zone on Monday. U.S. stocks closed lower on Friday amid concerns over the conflict in the Middle East, with the S&P 500 falling more than 1% during the session.
In Article Trend: Somewhat-Bearish
April 15, 2024 (20:47) / "Benzinga" (by Surbhi Jain)
J&J Braces For Q1 Earnings With Bearish Charts And Patent Cliffs In Play - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ, will be reporting its first-quarter earnings on April 16. Wall Street expects $2.64 in EPS and $21.4 billion in revenues as the company reports before market hours. Johnson & Johnson stock is down about 9.54% over the past year, and has dropped 5.88% YTD.
In Article Trend: Neutral
April 15, 2024 (20:23) / "Investors Business Daily" (by Investor's Business Daily)
Another Ugly Reversal; Tesla Dives On 'Dark Day'
Dow Jones Futures: Another Ugly Market Reversal. Nvidia Skids, Tesla Tumbles On 'Dark Day' Investor's Business Daily ...
In Article Trend: Neutral
April 15, 2024 (18:42) / "Benzinga" (by Vandana Singh)
Medical Device Manufacture Integer To Gain From Expanding Pulsed Field Ablation Market, Earns Upgrade From BofA Why Is Medical Device Manufacture Integer Stock Gaining Today? - Integer Holdings ( NYSE:ITGR )
BofA Securities upgraded Integer Holdings Corporation ITGR, citing the anticipated growth in pulsed field ablation ( PFA ) for treating atrial fibrillation. Integer is one of the largest medical device outsourcing manufacturers, serving the cardiac rhythm management, neuromodulation, ...
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:32) / "Barrons" (by Josh Nathan-Kazis)
Johnson & Johnson to Report Earnings as Talc Issues Loom
Johnson & Johnson Reports Earnings Tuesday. What to Expect. ...
In Article Trend: Neutral
April 15, 2024 (14:23) / "StockMarket.com" (by Jonathan Phillip)
3 Blue Chip Stocks For Your April 2024 Watchlist
The stock market serves as a central hub where investors can buy, sell, and trade shares of publicly traded companies. It is a key component of the global economy, reflecting the financial health and trends of industries and entire countries.
In Article Trend: Somewhat-Bullish
April 15, 2024 (14:06) / "Zacks Commentary" (by Kaibalya Pravo Dey)
Should You Buy Johnson & Johnson ( JNJ ) Ahead of Earnings?
Johnson & Johnson (JNJ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
In Article Trend: Bullish
April 15, 2024 (13:02) / "Zacks Commentary" (by Zacks Equity Research)
JPMorgan, Citigroup and even Wells Fargo are part of Zacks Earnings Preview
Chicago, IL - April 15, 2024 - Zacks.com releases the list of companies likely to issue earnings surprises. This week's list includes JPMorgan ( JPM Quick QuoteJPM - ) , Citigroup ( C Quick QuoteC - ) and even Wells Fargo ( WFC Quick QuoteWFC - ) .
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:38) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, ABIO, MODN - ARCA biopharma ( NASDAQ:ABIO ) , Apartment Income REIT ( NYSE:AIRC )
NEW YORK, April 15, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.
In Article Trend: Neutral
April 15, 2024 (12:19) / "Zacks Commentary" (by Nalak Das)
5 U.S. Bigwigs Likely to Gain on Q1 Earnings Beat This Week
We have narrowed our search to five large-cap stocks that are poised to beat on earnings results this week. These are: BAC, JNJ, UAL, PNC, BK.
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:03) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. ( Nasdaq - SWAV ) , Apartment Income REIT Corp. ( NYSE - AIRC ) , Model N, Inc. ( NYSE - MODN ) , ARCA biopharma, Inc. ( Nasdaq - ABIO )
BALA CYNWYD, Pa., April 15, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
April 15, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares U.S. Pharmaceuticals ETF ( IHE ) ?
Sector ETF report for ...
In Article Trend: Neutral
April 15, 2024 (06:15) / "PR Newswire" (by Respiree)
DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT JLABS @ SAN FRANCISCO
DIGITAL THERAPEUTICS STARTUP RESPIREE™ ANNOUNCES INCORPORATION IN US WITH RESIDENCY AT ... PR ...
In Article Trend: Somewhat-Bullish
April 14, 2024 (11:30) / "CNN" (by Bryan Mena)
Americans are savings less these days. Here's why and what that means | Business
Americans are saving less these days. Here's why and what that means ...
In Article Trend: Neutral
April 14, 2024 (11:00) / "Forbes" (by Bill Stone)
Inflation And Banks Drag Stocks Lower Despite Earnings
The earnings season began slowly last week, with only 10 S&P 500 companies reporting. Banks were a large contingent of the reporters, which boosted the sector's earnings expectations for the quarter as all the banks reported better-than-expected earnings.
In Article Trend: Neutral
April 14, 2024 (10:15) / "Motley Fool" (by and Lee Samaha)
If You Like This High-Yield Vanguard Fund, Then You'll Love These Two Dividend Stocks
Boost your passive income in a way that's right for you.
In Article Trend: Somewhat-Bullish
April 12, 2024 (21:54) / "Investors Business Daily" (by ALAN R. ELLIOTT)
Netflix, Goldman Sachs And The Bitcoin Halving: Investing Action Plan
A seesaw week took a turn for the better, then slammed into a financial-sector sell-off on Friday, following JPMorgan's earnings report. Goldman Sachs ( GS ) , Charles Schwab ( SCHW ) and Bank of America ( BAC ) are next up, with earnings due early in the week.
In Article Trend: Neutral
April 12, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Stock Moves -0.85%: What You Should Know
The latest trading day saw Johnson & Johnson (JNJ) settling at $147.52, representing a -0.85% change from its previous close.
In Article Trend: Neutral
April 12, 2024 (20:28) / "Zacks Commentary" (by Sheraz Mian)
The Q1 Earnings Season Kicks off Positively
We see the Q1 results from the major banks as good enough. not great, but definitely not bad either. Next week, the cycle picks up notable steam, with 41 S&P 500 companies on the reporting docket. How will the market react?
In Article Trend: Somewhat-Bullish
April 12, 2024 (19:00) / "Zacks Commentary" (by Zacks Investment Research)
3 Quarterly Releases to Watch Next Week
Earnings season is always an exciting time for investors, with companies finally revealing what's transpired behind closed doors. And concerning next week's docket, these three notable companies are scheduled to report.
In Article Trend: Somewhat-Bullish
April 12, 2024 (15:26) / "Benzinga" (by Chris Katje)
's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Constellation Energy ( NASDAQ:CEG ) , Chipotle Mexican Grill ( NYSE:CMG )
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks just under the surface and warrant attention. Investors are constantly on the hunt for undervalued, under-followed and emerging stocks.
In Article Trend: Somewhat-Bullish
April 12, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) to Begin Pharma Q1 Earnings Season: What's in Store?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
In Article Trend: Somewhat-Bullish
April 12, 2024 (12:55) / "GlobeNewswire" (by Chemometec A/S)
Clarification of guidance for revenue and lower than expected operating profit in the 2023/24 financial year
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
April 12, 2024 (12:00) / "Motley Fool" (by Daniel Foelber)
5 Dividend Kings That Yield More Than Vanguard's Top Value ETF
Despite a thriving bull market, some Dividend Kings still yield more than the Vanguard Value ETF's 2.4% payout.
In Article Trend: Somewhat-Bullish
April 12, 2024 (09:32) / "Benzinga" (by Avi Kapoor)
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket - NextPlat ( NASDAQ:NXPL )
Shares of NextPlat Corp NXPL rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged 29.8% to $1.96 in pre-market trading. Here are some other stocks moving in pre-market trading.
In Article Trend: Neutral
April 11, 2024 (19:21) / "Benzinga" (by Avi Kapoor)
Nasdaq Jumps 250 Points; Crude Oil Down 1% - Aptevo Therapeutics ( NASDAQ:APVO ) , Eliem Therapeutics ( NASDAQ:ELYM )
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26. Information technology shares rose by 2.2% on ...
In Article Trend: Neutral
April 11, 2024 (15:55) / "Benzinga" (by Avi Kapoor)
Dow Dips 100 Points; CarMax Earnings Miss Views - CarMax ( NYSE:KMX )
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday. The Dow traded down 0.35% to 38,328.18 while the NASDAQ rose 0.50% to 16,251.71. The S&P 500 also rose, gaining, 0.03% to 5,162.19.Check This Out: How To Earn $500 A Month From ...
In Article Trend: Neutral
April 11, 2024 (15:38) / "Forbes" (by Catherine Brock)
How To Get Steady Income: 6 Best Monthly Dividend ETFs
Dividend exchange-traded funds are the ultimate in passive income. You do the work upfront to evaluate the fund's strategy, then monitor results and count the money that's flowing in. And since the payout drops to your account monthly, it's almost like earning a paycheck-without the boss, ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (14:02) / "Benzinga" (by Gary Brode)
5 Things To Know In Investing This Week - The Shockwave Takeover Issue - Johnson & Johnson ( NYSE:JNJ ) , Shockwave Medical ( NASDAQ:SWAV )
The Shockwave offer that DKI predicted in December happened this week with Johnson & Johnson JNJagreeing to pay $335 per share in cash. DKI subscribers celebrated! The PMI came in hot. Don't want to read the details? The conclusion is "higher for longer".
In Article Trend: Neutral
April 11, 2024 (14:01) / "Benzinga" (by Avi Kapoor)
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday - Janux Therapeutics ( NASDAQ:JANX ) , Alpine Immune Sciences ( NASDAQ:ALPN ) , Enliven Therapeutics ( NASDAQ:ELVN )
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. ELVN rose sharply during Thursday's session. Enliven Therapeutics announced proof of concept data from Phase 1 clinical trial of ELVN-001 in chronic myeloid leukemia.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:41) / "Benzinga" (by Avi Kapoor)
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March - Aptevo Therapeutics ( NASDAQ:APVO ) , ClearOne ( NASDAQ:CLRO )
U.S. stocks traded mostly higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.03% to 38,472.80 while the NASDAQ rose 0.40% to 16,234.94. The S&P 500 also rose, gaining, 0.17% to 5,169.21. Real estate shares rose by 0.6% on Thursday.
In Article Trend: Somewhat-Bullish
April 11, 2024 (13:27) / "Benzinga" (by Vandana Singh)
Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher - Rallybio ( NASDAQ:RLYB ) , Johnson & Johnson ( NYSE:JNJ )
Rallybio Corporation RLYB shares are trading higher after the company announced a collaboration with Johnson & Johnson JNJ to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia ( FNAIT ) .
In Article Trend: Neutral
April 11, 2024 (13:15) / "Zacks Commentary" (by Zacks Equity Research)
Unlocking Q1 Potential of Johnson & Johnson ( JNJ ) : Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
In Article Trend: Neutral
April 11, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Investors Heavily Search Johnson & Johnson ( JNJ ) : Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
In Article Trend: Somewhat-Bullish
April 11, 2024 (12:41) / "Investors Business Daily" (by Investor's Business Daily)
Nike Stock Jumps On Upgrade As Estimates 'Finally Look Achievable' Ahead Of Paris Olympics
Nike stock rose early Thursday after the Dow Jones sports apparel behemoth received an upgrade from BofA Securities, citing the Paris Olympics as a catalyst. Rival sports retailers and footwear stocks were mixed Thursday morning.
In Article Trend: Somewhat-Bullish
April 11, 2024 (10:45) / "Benzinga" (by Zacks)
Boston Scientific ( BSX ) Faces Rising Costs, Competition - Boston Scientific ( NYSE:BSX ) , Cardinal Health ( NYSE:CAH )
Boston Scientific Corporation BSX has been struggling due to unfavorable currency movement and macroeconomic woes. Strong competitors in the large medical device market also pose a tough challenge for Boston Scientific. The stock carries a Zacks Rank #4 ( Sell ) currently.
In Article Trend: Neutral
April 11, 2024 (10:14) / "Benzinga" (by Avi Kapoor)
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket - Rallybio ( NASDAQ:RLYB )
Shares of Rallybio Corporation RLYB rose sharply in today's pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant individuals at risk of FNAIT. Rallybio shares jumped rose 77.9% to $2.90 in pre-market trading.
In Article Trend: Neutral
April 11, 2024 (06:00) / "GlobeNewswire" (by VIRTUALWARE 2007 SA)
INVESTOR CALL: Virtualware's CEO to present Annual Report to shareholders
Bilbao, April 11 - Spanish listed company Virtualware ( EPA:MLVIR ) , European leader in the industrial virtual reality sector, invites its shareholders to a meeting to review the Annual Results and Auditors' Report for the 2023 financial year.
In Article Trend: Somewhat-Bullish
April 10, 2024 (22:52) / "Forbes" (by Alex Knapp)
InnovationRx: $90 Million To Make Drugs In Space
InnovationRx is your weekly digest of healthcare news. To get it in your inbox, subscribe here. ess than a month after the company released the results of its first drug manufacturing experiment, Varda Space announced that it has raised a $90 million series B round, bringing its total investments ...
In Article Trend: Neutral
April 10, 2024 (15:10) / "Zacks Commentary" (by Sweta Killa)
What's in Store for Dow ETFs in Q1 Earnings?
Of the 16 Zacks sectors, eight are expected to post earnings growth in the first quarter, with the strongest gains in the Technology sector (19.4%).
In Article Trend: Somewhat-Bullish
April 10, 2024 (14:50) / "GlobeNewswire" (by Chemometec A/S)
April 10, 2024 (14:47) / "Benzinga" (by Upwallstreet)
The Pharmaceutical Industry Finds Itself At A Historical Crossroads - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers Squibb BMY, Merck & Co Inc MRK, Pfizer Inc PFE and Johnson & JohnsonJNJ are facing the so-called patent cliffs which imply revenue of tens of billions of dollars between now and and the end of this decade is at risk.
In Article Trend: Neutral
April 10, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Boston Scientific ( BSX ) Faces Rising Costs, Competition
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
In Article Trend: Neutral
April 10, 2024 (13:25) / "Benzinga" (by Globe Newswire)
SWAV Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Shockwave Medical to Johnson & Johnson - Shockwave Medical ( NASDAQ:SWAV )
MONSEY, N.Y., April 10, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the price of $335.00 per share in cash for which Shockwave Medical, Inc. SWAV ( "Shockwave" ) has agreed to be sold to Johnson & Johnson.
In Article Trend: Somewhat-Bullish
April 10, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
In Article Trend: Somewhat-Bullish
April 10, 2024 (12:30) / "Forbes" (by Trefis Team)
What's Next For Johnson & Johnson Stock After A 6% Decline In A Month?
Johnson & Johnson ( NYSE: JNJ ) recently announced its plans to acquire Shockwave Medical for $13 billion. Shockwave will help J&J extend its offerings in the cardiovascular intervention market.
In Article Trend: Somewhat-Bullish
April 10, 2024 (08:57) / "Motley Fool" (by David Jagielski)
Does Johnson & Johnson's Latest Acquisition Make It a No-Brainer Buy?
The company is hoping to expand, but is there enough here to attract growth investors?
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:37) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: J&J cell therapy gains new edge over Bristol Myers rival
J&J's cell therapy is now approved for an earlier line of treatment than a competing drug from Bristol Myers. Meanwhile, a look at Mount Sinai's approach to AI.
In Article Trend: Somewhat-Bullish
April 9, 2024 (15:00) / "Benzinga" (by Benzinga Insights)
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson ( NYSE:JNJ )
Amidst today's fast-paced and highly competitive business environment, it is crucial for investors and industry enthusiasts to conduct comprehensive company evaluations.
In Article Trend: Somewhat-Bullish
April 9, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Somewhat-Bullish
April 9, 2024 (13:51) / "Motley Fool" (by Motley Fool Staff)
How's AT&T Handling Things?
We've also got a look at 3M's spinoff, gold prices, and the beef industry.
In Article Trend: Somewhat-Bullish
April 9, 2024 (12:00) / "Canada Newswire" (by enGene Inc.)
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development Canada ...
In Article Trend: Neutral
April 9, 2024 (08:21) / "Motley Fool" (by Cory Renauer)
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
In Article Trend: Somewhat-Bullish
April 8, 2024 (21:50) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Johnson & Johnson ( JNJ ) Fell More Than Broader Market
In the latest trading session, Johnson & Johnson (JNJ) closed at $151.59, marking a -0.52% move from the previous day.
In Article Trend: Neutral
April 8, 2024 (21:31) / "PR Newswire" (by DelveInsight Business Research)
Giant-Cell Arteritis Market to Showcase Positive Growth at a CAGR of 9.3% by 2034 | DelveInsight
The growth of the giant-cell arteritis market is expected to be mainly driven by the growing geriatric population, the rise in the prevalence of cardiovascular disorders, technological advancements in the healthcare industry, and others.
In Article Trend: Somewhat-Bullish
April 8, 2024 (18:25) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, AIRC, MODN, ABIO - Apartment Income REIT ( NYSE:AIRC ) , ARCA biopharma ( NASDAQ:ABIO )
NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.
In Article Trend: Neutral
April 8, 2024 (18:19) / "Benzinga" (by Vandana Singh)
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population - Legend Biotech ( NASDAQ:LEGN ) , Johnson & Johnson ( NYSE:JNJ )
Friday, the FDA approved Johnson & Johnson JNJ Carvykti ( ciltacabtagene autoleucel; cilta-cel ) for relapsed or refractory multiple myeloma patients who have received at least one prior line of therapy and are refractory to lenalidomide.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:53) / "Business Insider" (by Vandana Singh)
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says
Johnson & Johnson ( NYSE:JNJ ) agreed on Friday to acquire Shockwave Medical Inc ( NASDAQ:SWAV ) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:27) / "Benzinga" (by Vandana Singh)
Johnson & Johnson's $13B Shockwave Medical Deal Accelerates MedTech Strategy, Analyst Says - Johnson & Johnson ( NYSE:JNJ ) , Shockwave Medical ( NASDAQ:SWAV )
Johnson & Johnson JNJ agreed on Friday to acquire Shockwave Medical Inc SWAV for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:27) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Label Expansion of Abecma
Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:23) / "Benzinga" (by MarketBeat)
Shockwave Medical Stock Rises After Johnson & Johnson Buyout - Johnson & Johnson ( NYSE:JNJ ) , Shockwave Medical ( NASDAQ:SWAV )
Shockwave Medical Inc SWAV is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson JNJ announced it would buy the company for $13.1 billion, boosting its portfolio of cardiovascular disease treatment devices.
In Article Trend: Somewhat-Bullish
April 8, 2024 (17:15) / "Forbes" (by Simon Mainwaring)
Fashion Workwear Brand Argent Helps Women In Every Field Drop-Kick The Glass Ceiling
Ninety-nine percent of the partnership opportunities that nine-year-old women's fashion workwear brand Argent considers never get a yes. "We've been really, really intentional with our collaborations," says CEO and founder Sali Christeson.
In Article Trend: Somewhat-Bullish
April 8, 2024 (16:48) / "Benzinga" (by Globe Newswire)
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Shockwave Medical, Inc. ( Nasdaq - SWAV ) , Apartment Income REIT Corp. ( NYSE - AIRC ) , Model N, Inc. ( NYSE - MODN ) , ARCA biopharma, Inc. ( Nasdaq - ABIO )
BALA CYNWYD, Pa., April 08, 2024 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
In Article Trend: Somewhat-Bullish
April 8, 2024 (14:15) / "Benzinga" (by Globe Newswire)
Dementia Drugs Market Size is projected to reach USD 26,795.69 million by 2030, growing at a CAGR of 7.95%: Straits Research
New York, United States, April 08, 2024 ( GLOBE NEWSWIRE ) -- Dementia is a term used to describe a group of symptoms that significantly impair memory, reasoning, and social abilities. The symptoms include cognitive and behavioral changes that worsen over time, making it difficult to perform even ...
In Article Trend: Neutral
April 8, 2024 (13:40) / "Zacks Commentary" (by Zacks Equity Research)
FDA Expands J&J's ( JNJ ) Carvykti Label in Multiple Myeloma
Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.
In Article Trend: Somewhat-Bullish
April 8, 2024 (13:18) / "Zacks Commentary" (by Zacks Equity Research)
J&J's ( JNJ ) $13.1B Shockwave Deal to Boost MedTech Cardio
J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.
In Article Trend: Somewhat-Bullish
April 8, 2024 (12:35) / "The Financial Express" (by Health Desk)
Johnson & Johnson's bone cancer drug gets USFDA nod
Johnson & Johnson on Monday announced that the US Food and Drug Administration ( FDA ) has approved Carvykti for the treatment of adult patients with relapsed or refractory multiple myeloma.
In Article Trend: Neutral
April 8, 2024 (11:30) / "Forbes" (by Trefis Team)
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals bellwether Johnson & Johnson ( NYSE: JNJ ) is currently a better pick over its peer AbbVie ( NYSE: ABBV ) .
In Article Trend: Somewhat-Bullish
April 8, 2024 (09:01) / "Money Control"
AstraZeneca, Daiichi drug gets broad tumor approval in US
The US Food and Drug Administration cleared the medicine for patients who have HER2-positive solid tumors that have spread or can't be removed with surgery, the company said. These patients have already received prior treatment and don't have any good alternatives.
In Article Trend: Somewhat-Bullish
April 8, 2024 (07:46) / "Motley Fool" (by Prosper Junior Bakiny)
2 Dividend Stocks to Buy and Hold Forever
These dividends are about as safe as they come.
In Article Trend: Somewhat-Bullish
April 7, 2024 (18:30) / "Motley Fool" (by Keith Speights)
Here's the $4.7 Trillion Market Nvidia Has Its Eyes on Now
The GPU maker hopes to make a bigger splash in a market that accounts for 18% of the U.S. GDP.
In Article Trend: Somewhat-Bullish
April 7, 2024 (14:46) / "Forbes" (by Omer Awan)
Examining High Drug Costs In America. What You Need To Know
Soaring drug prices in America have left many Americans unable to pay for medications and treatments that could otherwise improve their health and well-being. 58 million Americans experience medication insecurity, or the inability to pay for a medication in the last 12 months, according to a ...
In Article Trend: Neutral
April 7, 2024 (12:01) / "Forbes" (by Ge Bai)
More Risks, More Opportunities: What's Next For Employers In Healthcare?
More Risks, More Opportunities For Employers In Healthcare Forbes ...
In Article Trend: Somewhat-Bullish
April 7, 2024 (08:15) / "Motley Fool" (by Demitri Kalogeropoulos)
Want $200 Per Month in Passive Income? Invest $80,000 in This Vanguard ETF
Truly passive income is easy to find on the stock market.
In Article Trend: Somewhat-Bullish
April 6, 2024 (12:15) / "Motley Fool" (by Motley Fool Staff)
Can a New CEO Fix Boeing?
We also talk with e.l.f. Beauty CEO Tarang Amin about how the company is succeeding.
In Article Trend: Somewhat-Bullish
April 6, 2024 (04:14) / "Money Control"
Wall Street indexes rise after strong jobs data
The Dow Jones Industrial Average rose 307.06 points, or 0.80%, to 38,904.04, the SP 500 gained 57.13 points, or 1.11%, to 5,204.34 and the Nasdaq Composite gained 199.44 points, or 1.24%, to 16,248.52.
In Article Trend: Neutral
April 6, 2024 (01:38) / "PR Newswire" (by Halper Sadeh LLP)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ADTH, NVEI, SWAV
NEW YORK, April 5, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: sale to Cadent, LLC for $3.21 per share.
In Article Trend: Somewhat-Bullish
April 5, 2024 (19:27) / "Zacks Commentary" (by Shaun Pruitt)
Acquisition Watch: Time to Buy Johnson & Johnson ( JNJ ) or ShockWave Medical's ( SWAV ) Stock?
News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.
In Article Trend: Somewhat-Bullish
April 5, 2024 (18:01) / "Investors Business Daily" (by VIDYA RAMAKRISHNAN)
Stocks Buck Strong Jobs Data; Nvidia Tests This Key Level As Tesla Falls On Stock Market Today
Stocks Buck Strong Jobs Data. Nvidia Tests This Key Level As Tesla Falls Investor's Business Daily ...
In Article Trend: Neutral
April 5, 2024 (17:44) / "Benzinga" (by Globe Newswire)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWAV, KTRA, ABIO - ARCA biopharma ( NASDAQ:ABIO ) , Kintara Therapeutics ( NASDAQ:KTRA )
NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Shockwave Medical, Inc.
In Article Trend: Neutral
April 5, 2024 (16:00) / "Benzinga" (by Globe Newswire)
CURE Media Group and Oncology Nursing News announce Kristen Dahlgren as keynote speaker for the 2024 Extraordinary Healer® event
CRANBURY, N.J., April 05, 2024 ( GLOBE NEWSWIRE ) -- CURE® Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to more than 1 million patients, survivors and caregivers, partners with Oncology Nursing News®, a multimedia platform dedicated to ...
In Article Trend: Bullish
April 5, 2024 (15:45) / "Investors Business Daily" (by Investor's Business Daily)
Uptrend Under Pressure; Tesla, Humana In Focus: Weekly Review
Uptrend Under Pressure. Tesla, Humana In Focus: Weekly Review Investor's Business Daily ...
In Article Trend: Neutral
April 5, 2024 (14:49) / "Investors Business Daily" (by KEN SHREVE)
Stock Market Heads Higher After Robust Jobs Data; Tech Rally Led By Amazon, AMD, Netflix
Stock Market Heads Higher After Robust Jobs Data. Tech Rally Led By Amazon, AMD, Netflix Investor's Business Daily ...
In Article Trend: Neutral
April 5, 2024 (14:23) / "Associated Press" (by DAMIAN J. TROISE)
Stock market today: Wall Street gains ground following surprisingly strong US jobs report
Stock market today: Wall Street edges higher following surprisingly strong US jobs report The Associated Press ...
In Article Trend: Neutral
April 5, 2024 (14:01) / "Forbes" (by Ty Roush)
Johnson & Johnson Buys Shockwave For $13.1 Billion In Latest Cardio Deal
Johnson & Johnson will acquire Shockwave Medical in a deal valued at $13.1 billion, according to a joint statement Friday, the latest acquisition by the pharmaceutical firm over the last two years as it expands on cardiovascular intervention.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:56) / "Associated Press" (by TOM MURPHY)
J&J to pump another $13B into its MedTech business with Shockwave deal
Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries. The health care giant said Friday that it will spend $335 in cash for each share of Shockwave.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:35) / "Benzinga" (by Vandana Singh)
Johnson & Johnson Makes Yet Another Multi-Billion MedTech Deal With Shockwave Medical - Johnson & Johnson ( NYSE:JNJ ) , Shockwave Medical ( NASDAQ:SWAV )
Friday, Johnson & Johnson JNJ agreed to acquire Shockwave Medical Inc SWAV for $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including cash acquired.
In Article Trend: Somewhat-Bullish
April 5, 2024 (12:05) / "Investors Business Daily" (by Investor's Business Daily)
Futures Bounce Ahead Of Jobs Report
Stock Market Today: Dow Jones Bounces Ahead Of Jobs Report. Meta, Nvidia, Tesla Rally Investor's Business Daily ...
In Article Trend: Neutral
April 5, 2024 (11:12) / "Barrons" (by Adam Clark)
Johnson & Johnson to Buy Shockwave Medical. It's a Cardio Health Play.
Johnson & Johnson agreed to acquire medical-devices maker Shockwave Medical for a total enterprise value of about $13.1 billion. Johnson & Johnson will pay $335 a share in cash for Shockwave , J&J said in a statement Friday.
In Article Trend: Somewhat-Bullish
)
April 5, 2024 (11:06) / "Business Standard" (by Reuters)
Johnson & Johnson to buy equipment maker Shockwave Medical for $12.5 bn
Johnson & Johnson on Friday agreed to buy Shockwave Medical for $12.5 billion, in a deal that would help broaden its portfolio of medical devices used in treating heart diseases.
In Article Trend: Somewhat-Bullish
April 5, 2024 (10:55) / "Investors Business Daily" (by Investor's Business Daily)
Johnson & Johnson To Buy Shockwave Medical For $13.1 Billion
Dow Jones giant Johnson & Johnson ( JNJ ) said it would acquire Shockwave Medical ( SWAV ) for $13.1 billion, or $335 a share. Both stocks rose slightly early Friday. SWAV stock had surged 68% to 319.99 as of April 4 in 2024, with takeover speculation among the driving forces.
In Article Trend: Neutral
April 5, 2024 (01:02) / "GlobeNewswire" (by Contineum Therapeutics)
Contineum Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...
In Article Trend: Neutral
April 5, 2024 (01:02) / "Benzinga" (by Globe Newswire)
Contineum Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, April 04, 2024 ( GLOBE NEWSWIRE ) -- Contineum Therapeutics, Inc. ( Contineum ) , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the ...
In Article Trend: Neutral
April 4, 2024 (12:45) / "Benzinga" (by Globe Newswire)
Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth
STUDIO CITY, Calif., April 04, 2024 ( GLOBE NEWSWIRE ) -- At the conclusion of this year's Myeloma Action Month, the International Myeloma Foundation ( IMF ) was truly grateful and overwhelmed by everyone's support in making the annual campaign a global success -with over 52 million reached in ...
In Article Trend: Bullish
April 4, 2024 (11:30) / "GlobeNewswire" (by Trinity Biotech plc)
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
DUBLIN, Ireland, April 04, 2024 ( GLOBE NEWSWIRE ) -- Trinity Biotech plc ( Nasdaq: TRIB ) , a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and ...
In Article Trend: Neutral
April 4, 2024 (11:05) / "Benzinga" (by Globe Newswire)
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board - NextCure ( NASDAQ:NXTC )
BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. NXTC, a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to its Scientific ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (11:05) / "GlobeNewswire" (by NextCure)
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
BELTSVILLE, Md., April 04, 2024 ( GLOBE NEWSWIRE ) -- NextCure, Inc. ( Nasdaq: NXTC ) , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of Rakesh Dixit, PhD, to ...
In Article Trend: Somewhat-Bullish
April 4, 2024 (11:00) / "Zacks Commentary" (by Sanghamitra Saha)
Time to Tap Healthcare ETFs on Nvidia's AI Ambition?
At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.
In Article Trend: Somewhat-Bullish
April 3, 2024 (16:10) / "Zacks Commentary" (by Zacks Equity Research)
Will Johnson & Johnson ( JNJ ) Beat Estimates Again in Its Next Earnings Report?
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
In Article Trend: Bullish
April 3, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Robust Growth Expected In The Intestinal Pseudo Obstruction Treatment Market: Market To Grow At A Rate Of More Than 5% Through 2024-2028 As Per TBRC's Intestinal Pseudo Obstruction Treatment Global Market Report 2024
LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Intestinal Pseudo Obstruction Treatment Global Market Report 2024, the intestinal pseudo obstruction treatment market has witnessed strong growth in recent years, with the market size projected to increase from ...
In Article Trend: Neutral
April 3, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Transformative Growth Expected In The Global Medical Equipment Market: Market Size To Reach $1,077 Billion By 2028 As Per The Business Research Company's Medical Equipment Global Market Report 2024
LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Medical Equipment Global Market Report 2024, the medical equipment market has witnessed robust growth in recent years, with the market size expected to reach $775.42 billion in 2024, reflecting a compound annual ...
In Article Trend: Somewhat-Bullish
April 3, 2024 (14:23) / "Benzinga" (by Gary Brode)
5 Things to Know in Investing This Week - Boston Scientific ( NYSE:BSX ) , Johnson & Johnson ( NYSE:JNJ )
The Personal Consumption Expenditures ( PCE ) Index is the preferred inflation metric for the Federal Reserve. This month's report came out during Good Friday when the markets are closed. Within hours, the hawks who favor higher rates and the doves who favor lower rates all claimed the report ...
In Article Trend: Neutral
April 3, 2024 (14:05) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - Swedbank Robur Fonder AB
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
April 3, 2024 (12:50) / "Zacks Commentary" (by Zacks Equity Research)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
In Article Trend: Bullish
April 3, 2024 (04:00) / "PR Newswire"
Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 - PR Newswire
Great Place To Work unveils Top 10 Best Workplaces in Singapore Healthcare and Biopharma™ 2024 PR ...
In Article Trend: Bullish
April 2, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Stock Moves -0.03%: What You Should Know
The latest trading day saw Johnson & Johnson (JNJ) settling at $157.73, representing a -0.03% change from its previous close.
In Article Trend: Neutral
April 2, 2024 (20:15) / "GlobeNewswire" (by Nanobiotix S.A.)
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
PARIS and CAMBRIDGE, Mass., April 02, 2024 ( GLOBE NEWSWIRE ) -- NANOBIOTIX ( Euronext : NANO -- NASDAQ: NBTX - the ''Company'' ) , a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced ...
In Article Trend: Neutral
April 2, 2024 (14:40) / "Benzinga" (by Globe Newswire)
Cytokine Market Size is projected to reach USD 148.56 billion by 2031, growing at a CAGR of 8.40%: Straits Research
New York, United States, April 02, 2024 ( GLOBE NEWSWIRE ) -- A cytokine is a collection of proteins, peptides, or glycoproteins released by particular cells to regulate the development and function of the immune system and blood cells.
In Article Trend: Neutral
April 2, 2024 (12:00) / "Zacks Commentary" (by Sanghamitra Saha)
AI ETFs: Q1 of 2024 Update
The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.
In Article Trend: Somewhat-Bullish
April 1, 2024 (21:06) / "Motley Fool" (by Jeremy Bowman)
Why 3M Stock Was Moving Higher Today
Investors applauded the spin-off of its healthcare business.
In Article Trend: Somewhat-Bullish
April 1, 2024 (15:00) / "Motley Fool" (by Justin Pope)
3 Reasons You Can Buy This "Magnificent Seven" Stock and Hold It Forever
Buy and hold forever is a bold ask. However, Microsoft delivers across the board.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:30) / "Benzinga" (by Benzinga Insights)
Looking Into Johnson & Johnson's Recent Short Interest - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson's JNJ short percent of float has risen 6.45% since its last report. The company recently reported that it has 15.84 million shares sold short, which is 0.66% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
April 1, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Reasons to Add ShockWave Medical ( SWAV ) to Your Portfolio Now
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
In Article Trend: Somewhat-Bullish
April 1, 2024 (13:00) / "GlobeNewswire" (by Spectral AI)
Spectral AI Appoints Jeremiah Sparks as Chief Commercialization Officer
Experienced Burn Industry Executive Champions Pivot to Commercialization Experienced Burn Industry Executive Champions Pivot to Commercialization ...
In Article Trend: Somewhat-Bullish
April 1, 2024 (12:14) / "PR Newswire"
United Airlines Names Michelle Freyre to Board of Directors - PR Newswire
United Airlines Names Michelle Freyre to Board of Directors PR ...
In Article Trend: Bullish
April 1, 2024 (10:52) / "Zacks Commentary" (by Zacks Equity Research)
3 VALIC Mutual Funds for Consistent Returns
Invests in VALIC Mutual Funds like VCAAX, VCULX and VBCVX for tax-efficient wealth growth.
In Article Trend: Somewhat-Bullish
April 1, 2024 (10:30) / "Forbes" (by Maneet Ahuja)
Meet The Billionaire Bond Investor Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers
Meet The Billionaire Bond Trader Behind Chelsea F.C., Springsteen's Songbook And The LA Dodgers Forbes ...
In Article Trend: Somewhat-Bullish
March 31, 2024 (21:43) / "Forbes" (by Jack Magruder)
WM Phoenix Open Delivers Refunds To About 2,800 Fans After Ticket Snafu
The "People's Open" is attempting to make its people whole. The WM Phoenix Open - which bills itself as the People's Open because of the overwhelming support it receives from the local golf community - has given refunds to about 2,800 ticket holders who were denied entrance to the third round of ...
In Article Trend: Neutral
March 31, 2024 (07:10) / "Motley Fool" (by Rachel Warren)
2024 S&P 500 Bull Market: 2 Unstoppable Growth Stocks to Buy Right Now
The fresh bull market is attracting investors of all trading styles.
In Article Trend: Somewhat-Bullish
March 30, 2024 (09:19) / "Motley Fool" (by Cory Renauer)
3 Reliable Dividend Growth Stocks With Yields Above 3% That You Can Buy Now and Hold for at Least a Decade
These advantaged businesses have what it takes to keep raising their payouts.
In Article Trend: Somewhat-Bullish
March 29, 2024 (21:41) / "GlobeNewswire" (by Titan Medical Inc.)
Titan Medical Reports Fiscal Year 2023 Results
TORONTO, Ontario, March 29, 2024 ( GLOBE NEWSWIRE ) -- Titan Medical Inc. ( "Titan" or the "Company" ) ( TSX: TMD. OTC: TMDIF ) , today reported financial results for the fiscal year ended December 31, 2023.
In Article Trend: Somewhat-Bullish
March 29, 2024 (14:28) / "CNBC" (by Ian Thomas)
Microsoft, Salesforce woo skeptical CFOs on new generative AI tool spending
Salesforce and Microsoft are among the enterprise software giants trying to convince hesitant CFOs to spend on new finance-focused generative AI tools.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Here is What to Know Beyond Why Johnson & Johnson ( JNJ ) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
In Article Trend: Somewhat-Bullish
March 29, 2024 (13:00) / "Motley Fool" (by Danny Vena)
Why Shockwave Medical Stock Rallied as Much as 18% Higher This Week
Buyout rumors and love from Wall Street propelled the stock to double-digit gains.
In Article Trend: Somewhat-Bullish
March 28, 2024 (17:17) / "Forbes" (by Sandy Carter)
5 New Advancements In AI And Web3: Base, Meme Coins, Bitcoin Halving
In Lewis Carroll's classic, "Alice in Wonderland," the Red Queen tells Alice that in her kingdom, "it takes all the running you can do, to keep in the same place." This vivid metaphor is apt for the current pace of technological change, particularly in the realms of artificial intelligence ( AI ...
In Article Trend: Bullish
March 28, 2024 (16:58) / "Benzinga" (by Vandana Singh)
Johnson & Johnson Has An Opportunity In Talc-Cancer Lawsuit, Can Challenge Scientific Evidence In Federal Ruling - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ reportedly has an opportunity to challenge the scientific evidence linking talc to ovarian cancer, as U.S. District Judge Michael Shipp ruled on Wednesday.
In Article Trend: Somewhat-Bearish
March 28, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Shockwave Medical ( SWAV ) Up on Potential Acquisition Rumors
Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors - Compass Pathways ( NASDAQ:CMPS )
LONDON, March 28, 2024 ( GLOBE NEWSWIRE ) -- Compass Pathways plc CMPS ( "Compass" ) , a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that Board Chair and co-founder George Goldsmith and fellow co-founder Ekaterina ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (12:00) / "Zacks Commentary" (by Sanghamitra Saha)
4 Best ETF Areas of Q1
Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.
In Article Trend: Neutral
March 28, 2024 (10:15) / "Motley Fool" (by David Jagielski)
3 Dividend Stocks That Are Likely to Raise Their Payouts in April
Dividend increases should soon be coming from these stocks, but be careful -- it doesn't mean all of them are great buys.
In Article Trend: Somewhat-Bullish
March 28, 2024 (03:12) / "Business Standard" (by Reuters)
J&J can contest evidence linking its talc to ovarian cancer, says US judge
Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S.
In Article Trend: Neutral
March 27, 2024 (21:18) / "Forbes" (by Sara Dorn)
Bernie Sanders Calls On Novo Nordisk To Lower Cost Of Ozempic And Wegovy
Sen. Bernie Sanders, I-Vt., demanded Novo Nordisk, the Danish drug company that manufactures the wildly popular Ozempic and Wegovy weight loss drugs, lower the list price of the drugs, warning the "outrageously high price has the potential to bankrupt Medicare, the American people and our entire ...
In Article Trend: Neutral
March 27, 2024 (20:23) / "Benzinga" (by Vandana Singh)
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst - Boston Scientific ( NYSE:BSX ) , Johnson & Johnson ( NYSE:JNJ ) , Medtronic ( NYSE:MDT ) , Shockwave Medical ( NASDAQ:SWAV )
Tuesday, Shockwave Medical Inc SWAV shares traded higher following a Wall Street Journal report suggesting Johnson & Johnson JNJ is reportedly in talks to acquire the company. Shockwave Medical is a cardiovascular medical device.
In Article Trend: Somewhat-Bullish
March 27, 2024 (19:07) / "Investors Business Daily" (by Investor's Business Daily)
Shockwave Medical Stock Sees Relative Strength Rating Ride Higher
On Wednesday, Shockwave Medical ( SWAV ) stock got a positive adjustment to its Relative Strength ( RS ) Rating, from 90 to 94. The stock has been rallying amid a Wall Street Journal report that Johnson and Johnson ( JNJ ) is in talks to buy Shockwave Medical.
In Article Trend: Bullish
March 27, 2024 (15:04) / "PR Newswire"
Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President - PR Newswire
Neptune Strengthens Americas Sales Leadership with the Appointment of Jeff Piszczek as Vice President PR ...
In Article Trend: Bullish
March 27, 2024 (12:39) / "Zacks Commentary" (by Zacks Equity Research)
Merck ( MRK ) Gets FDA Approval for New PAH Drug Winrevair
Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.
In Article Trend: Somewhat-Bullish
March 27, 2024 (12:13) / "Benzinga" (by Avi Kapoor)
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields - Johnson & Johnson ( NYSE:JNJ ) , Gilead Sciences ( NASDAQ:GILD )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
In Article Trend: Neutral
March 27, 2024 (02:56) / "Benzinga" (by Benzinga Neuro)
Bank Of America Bullish On AI: Spotlights Top Supply Chain Stocks To Watch - NVIDIA ( NASDAQ:NVDA ) , Alchip Techs ( OTC:ALCPF )
Bank of America has identified key global stocks along the AI supply chain, including several NVIDIA Corp NVDA suppliers poised to benefit from the AI boom. What Happened: BofA highlighted the booming AI market and the potential for smaller firms in the global AI supply chain to benefit, reported ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Why the Market Dipped But Johnson & Johnson ( JNJ ) Gained Today
In the latest trading session, Johnson & Johnson (JNJ) closed at $155.77, marking a +0.35% move from the previous day.
In Article Trend: Neutral
March 26, 2024 (21:06) / "CNN" (by Brenda Goodman)
FDA approves new drug that may help stop and even reverse a rare, fatal condition that doctors call a 'ticking time bomb'
When doctors told Katrina Barry that she had a rare and serious condition called pulmonary arterial hypertension or PAH, they warned her not to Google it. Come on, she thought.
In Article Trend: Neutral
March 26, 2024 (19:53) / "Benzinga" (by Erica Kollmann)
What's Going On With Shockwave Medical Stock? - Shockwave Medical ( NASDAQ:SWAV )
Shockwave Medical, Inc. SWAV shares are trading higher Tuesday following a report suggesting Johnson & Johnson JNJ is in talks to acquire the company. According to a report from the Wall Street Journal, people familiar with the matter say that a deal to acquire the company could be completed in ...
In Article Trend: Somewhat-Bullish
March 26, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the iShares U.S. Healthcare ETF ( IYH ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Assessing Johnson & Johnson's Performance Against Competitors In Pharmaceuticals Industry - Johnson & Johnson ( NYSE:JNJ )
In the fast-paced and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating Johnson & Johnson JNJ in comparison to its major competitors within the ...
In Article Trend: Somewhat-Bullish
March 25, 2024 (15:31) / "Benzinga" (by Anusuya Lahiri)
Nvidia's AI Revolution Is Transforming Healthcare with Johnson & Johnson and GE Healthcare Partnerships - NVIDIA ( NASDAQ:NVDA )
Last week, Nvidia Corp NVDA announced significant collaborations with Johnson & Johnson JNJ and General Electric Co GE GE Healthcare to integrate generative AI into surgery and enhance medical imaging.
In Article Trend: Somewhat-Bullish
March 25, 2024 (14:20) / "Zacks Commentary" (by Zacks Equity Research)
GE HealthCare ( GEHC ) Uses AI Solution to Boost Medical Imaging
GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.
In Article Trend: Somewhat-Bullish
March 25, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Health Care Select Sector SPDR ETF ( XLV ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
March 24, 2024 (14:18) / "CNBC" (by Michelle Castillo)
Nvidia's AI ambitions in medicine and health care are becoming clear
Applying Nvidia AI chips to health care, whether it's biotechnology, chemicals, or drug discovery is going to be a big business.
In Article Trend: Neutral
March 24, 2024 (09:30) / "Motley Fool" (by Selena Maranjian)
Want $1 Million in Retirement? 9 ETFs to Buy Now and Hold for Decades.
Parking some of your dollars in high-performing sector ETFs may juice your portfolio's returns.
In Article Trend: Somewhat-Bullish
March 22, 2024 (22:35) / "PR Newswire" (by Johnson & Johnson)
U.S. FDA Approves OPSYNVI® ( macitentan and tadalafil ) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension ( PAH )
U.S. FDA Approves OPSYNVI® ( macitentan and tadalafil ) as the First and Only Once-Daily Single-Tablet Combination ... PR ...
In Article Trend: Neutral
March 22, 2024 (16:18) / "PR Newswire"
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... - PR Newswire
Pharmaceuticals Market In Germany size is set to grow by USD 21.44 bn from 2023-2027, Abbott Laboratories, AbbVie ... PR ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (16:00) / "PR Newswire" (by Research and Markets)
Vaccine Market Insights Revealed in New 2024 Global Industry Report
DUBLIN, March 22, 2024 /PRNewswire/ -- The "The World Market for Vaccines, 2024" report has been added to ResearchAndMarkets.com's offering. The healthcare landscape is ever-evolving, and as infectious diseases continue to be a global concern, the vaccine market remains a critical area of focus ...
In Article Trend: Somewhat-Bullish
March 22, 2024 (15:08) / "Benzinga" (by Globe Newswire)
CIO Leadership: The Call for Cybersecurity Innovation will Power the Discussion at the 13th Annual Washington, D.C. C-Level Technology Leadership Summit on April 18
WESTPORT, Conn., March 22, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its 13th Annual Washington, D.C.
In Article Trend: Somewhat-Bullish
March 22, 2024 (15:06) / "Forbes" (by John P. Reese)
Gaining An Edge: 5 AI-Powered Strategies For Stock Market Success
In the fast-paced world of investing, staying ahead of the curve is crucial for success. As artificial intelligence ( AI ) continues to transform various industries, savvy investors are turning to AI-powered tools and strategies to gain a competitive advantage in the stock market.
In Article Trend: Bullish
March 22, 2024 (12:30) / "Investors Business Daily" (by ROBERT POWELL)
GMO Quality Fund Aims To Beat Its Decade-Long Outperformance
Though past performance is not indicative of future results, the decade-long exceptional track record of the GMO Quality Fund - a top winner in Investor's Business Daily's 2024 Best Mutual Funds Awards - deserves some special attention.
In Article Trend: Somewhat-Bullish
March 22, 2024 (08:25) / "Motley Fool" (by Prosper Junior Bakiny)
Want Decades of Passive Income? 2 Stocks to Buy Now.
There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.
In Article Trend: Somewhat-Bullish
March 21, 2024 (18:31) / "Benzinga" (by Vandana Singh)
Johnson & Johnson's Abiomed Unit Recalls Instructions For Some Impella Blood Pumps Due To Cutting Risks - Johnson & Johnson ( NYSE:JNJ )
On Thursday, Johnson & Johnson's JNJ Abiomed said it is recalling its Impella Left Sided Blood Pumps because the pump catheter may perforate ( cut ) the wall of the left ventricle in the heart. During operations, the Impella device could cut through the wall of the left ventricle.
In Article Trend: Neutral
March 21, 2024 (12:45) / "Motley Fool" (by Prosper Junior Bakiny)
1 Magnificent Growth Stock to Buy and Hold
Investing in this company 10 years ago would have produced excellent returns, but it's not too late -- far from it.
In Article Trend: Somewhat-Bullish
March 21, 2024 (11:53) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets EC Nod for Abecma's Label Expansion
Bristol Myers (BMY) wins European Commission's approval for the label expansion of its CAR T cell immunotherapy Abecma in earlier lines for triple-class exposed relapsed and refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 21, 2024 (09:02) / "Motley Fool" (by Matt DiLallo)
Should You Buy 3M Before April 1?
A looming stock spinoff should give investors a reason to pause.
In Article Trend: Somewhat-Bullish
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a summary of recent pipeline and corporate highlights.
In Article Trend: Neutral
March 20, 2024 (20:15) / "GlobeNewswire" (by Alvotech)
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
REYKJAVIK, Iceland, March 20, 2024 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2023 and provided a ...
In Article Trend: Neutral
March 20, 2024 (15:30) / "Benzinga" (by The Bamboo Works)
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy - Johnson & Johnson ( NYSE:JNJ ) , Bristol-Myers Squibb ( NYSE:BMY )
GenScript's cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend's Carvykti is expected to hit annual production capacity of 10,000 doses by the end of 2025
In Article Trend: Neutral
March 20, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Migraine Drugs Market Continues To Surge At A Rate Of More Than 6%, Fueled By Innovation And Demand As Per The Business Research Company's Migraine Drugs Global Market Report 2024
LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Migraine Drugs Global Market Report 2024, the migraine drugs market has experienced robust growth in recent years, with promising projections for the future.
In Article Trend: Bullish
March 20, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Interstitial Cystitis Drugs Market Witnesses Robust Growth, Predicted To Surge At A Rate Of More Than 5% Through 2024-2028 As Per The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024
LONDON, March 20, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Interstitial Cystitis Drugs Global Market Report 2024, the interstitial cystitis drugs market has experienced significant growth in recent years, with notable projections indicating continued expansion.
In Article Trend: Bullish
March 20, 2024 (03:03) / "Benzinga" (by Benzinga Neuro)
Jim Cramer Reveals Nvidia's Non-Tech Partners That Can Be Potential Market Winner: 'Best Opportunities' - Getty Images Holdings ( NYSE:GETY ) , GE HealthCare Techs ( NASDAQ:GEHC )
CNBC host Jim Cramer has spotlighted several lesser-known partners of NVIDIA Corp NVDA that could potentially benefit from the company's advanced artificial intelligence ( AI ) technology.
In Article Trend: Somewhat-Bullish
March 19, 2024 (18:20) / "Benzinga" (by Globe Newswire)
US Retinal Specialists Highlight the Greatest Opportunity for Gene Therapies
EXTON, PA, March 19, 2024 ( GLOBE NEWSWIRE ) -- Gene therapies have emerged as a ray of hope, particularly in the realm of eye diseases. The focus on the eye has provided researchers with a promising pathway for delivering genetic material with precision and safety.
In Article Trend: Somewhat-Bullish
March 19, 2024 (15:40) / "Benzinga" (by Globe Newswire)
Cartilage Repair Market Anticipates Rapid Growth, Projected To Reach $2.3 Billion In 2028 As Per The Business Research Company's Cartilage Repair Global Market Report 2024
LONDON, March 19, 2024 ( GLOBE NEWSWIRE ) -- The Business Research Company's Cartilage Repair Market Global Report 2024 forecasts significant growth, with the cartilage repair market size expected to rise from $1.24 billion in 2023 to $1.42 billion in 2024, demonstrating a compound annual growth ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (14:51) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) , Nvidia Unite to Boost AI for Surgery
Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
In Article Trend: Somewhat-Bullish
March 19, 2024 (10:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the Vanguard Health Care ETF ( VHT ) ?
Sector ETF report for ...
In Article Trend: Somewhat-Bullish
)
March 19, 2024 (03:11) / "Business Standard" (by Bloomberg)
Nvidia CEO Jensen Huang unveils successor to its all-conquering AI chip
A new processor design called Blackwell is multiple times faster at handling the models that underpin AI, the company said at its GTC conference in San Jose, California. That includes the process of developing the technology - a stage known as training - and the running of it, which is called ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Stock Dips While Market Gains: Key Facts
Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.
In Article Trend: Somewhat-Bullish
March 18, 2024 (14:16) / "Benzinga" (by Vandana Singh)
Why Is 2seventy bio Stock Trading Higher On Monday? - Legend Biotech ( NASDAQ:LEGN ) , Johnson & Johnson ( NYSE:JNJ ) , 2seventy bio ( NASDAQ:TSVT ) , Bristol-Myers Squibb ( NYSE:BMY )
Friday, the FDA's Oncologic Drugs Advisory Committee ( ODAC ) voted positively ( 8-3 ) favoring expanded use of Bristol Myers Squibb & Co BMY 2seventy bio Inc's TSVT Abecma ( idecabtagene vicleucel ) .
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:31) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers' ( BMY ) Abecma Gets ODAC Votes for Label Expansion
Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
In Article Trend: Somewhat-Bullish
March 18, 2024 (13:00) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) is Attracting Investor Attention: Here is What You Should Know
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 18, 2024 (11:32) / "GlobeNewswire" (by Chemometec A/S)
March 18, 2024 (11:28) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - AIM International Mutual Funds
ANNOUNCEMENT NO. ...
In Article Trend: Somewhat-Bullish
March 18, 2024 (11:25) / "GlobeNewswire" (by Chemometec A/S)
March 18, 2024 (11:05) / "Benzinga" (by Globe Newswire)
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer - Clearside Biomedical ( NASDAQ:CLSD )
ALPHARETTA, Ga., March 18, 2024 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc. CLSD, a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space ( SCS® ) , announced today that Victor Chong, M.D., MBA was appointed Chief Medical ...
In Article Trend: Neutral
March 18, 2024 (10:55) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Gets FDA Panel Vote for Carvykti's Expanded Use
J&J (JNJ) is looking for expansion of Carvykti's label for the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma.
In Article Trend: Somewhat-Bullish
March 18, 2024 (01:12) / "PR Newswire"
India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... - PR Newswire
India Baby Care Products Market size to grow by USD 15.69 billion from 2022 to 2027, Market is fragmented due to the ... PR ...
In Article Trend: Somewhat-Bullish
March 17, 2024 (11:30) / "Motley Fool" (by Keith Speights)
Investing $10,000 in Each of These 3 Vanguard ETFs Could Generate $1,164 per Year in Passive Income
These funds provide investors with an easy way to rake in passive income.
In Article Trend: Somewhat-Bullish
March 16, 2024 (13:00) / "Motley Fool" (by Motley Fool Staff)
Market Cap Game Show: Matt Argersinger vs. Bill Mann
Test your knowledge of companies' value on the stock market.
In Article Trend: Somewhat-Bullish
March 16, 2024 (07:55) / "Motley Fool" (by David Jagielski)
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Johnson & Johnson's days of being a top healthcare stock could be long gone.
In Article Trend: Neutral
March 15, 2024 (16:33) / "Investors Business Daily" (by ALLISON GATLIN)
Why Abbott's Formula Selloff Could Be A Buying Opportunity, Says Analyst
Abbott Stock Dives As Fellow Formula Maker Fined $60 Million Following Infant Death Investor's Business Daily ...
In Article Trend: Neutral
March 15, 2024 (14:30) / "PR Newswire" (by MarketsandMarkets)
Monoclonal Antibody ( mABs ) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
CHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody ( mABs ) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a new report by ...
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:19) / "Zacks Commentary" (by Kinjel Shah)
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More
AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
In Article Trend: Somewhat-Bullish
March 15, 2024 (13:14) / "Zacks Commentary" (by Zacks Equity Research)
Bristol Myers ( BMY ) Gets FDA Nod for Breyanzi's Label Expansion
Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In Article Trend: Neutral
March 14, 2024 (20:03) / "Benzinga" (by Vandana Singh)
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus - AstraZeneca ( NASDAQ:AZN ) , Johnson & Johnson ( NYSE:JNJ )
Amid the ongoing scrutiny from Congress, WuXi AppTec and its affiliates face another setback as the Biotechnology Innovation Organization ( BIO ) , a U.S. industry lobbying group, severs ties with the Chinese biotech.
In Article Trend: Neutral
March 14, 2024 (19:59) / "Benzinga" (by Vandana Singh)
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits - Bayer ( OTC:BAYRY ) , Bayer ( OTC:BAYZF )
Bayer AG BAYRY BAYZF is reportedly considering utilizing the Texas Two-Step bankruptcy approach to tackle the onslaught of lawsuits in the United States implicating its Roundup weedkiller causing cancer.
In Article Trend: Neutral
March 14, 2024 (12:00) / "Zacks Commentary" (by Zacks Investment Research)
The Zacks Analyst Blog Highlights UnitedHealth Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar.
UnitedHealth, Johnson & Johnson, Oracle, Wells Fargo & Co and Caterpillar are the part of the Zacks top Analyst Blog .
In Article Trend: Somewhat-Bullish
March 14, 2024 (11:00) / "GlobeNewswire" (by AC Immune SA)
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update • ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 • ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track for interim data in H2 • Cash of CHF 103 million at year end, ...
In Article Trend: Neutral
March 14, 2024 (09:48) / "Benzinga" (by Globe Newswire)
Cellulite Treatment Market Projected to Expand at a CAGR of 10.2%, Elevating to a Valuation of USD 1.7 billion by 2031: Transparency Market Research, Inc.
Wilmington, Delaware, United States, March 14, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The cellulite treatment market was worth US$ 710.8 million in 2022. By the end of 2031, it is estimated to reach US$ 1.7 billion, increasing at a CAGR of 10.2% during the forecast period.
In Article Trend: Somewhat-Bullish
March 13, 2024 (17:43) / "Benzinga" (by Vandana Singh)
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers - Johnson & Johnson ( NYSE:JNJ ) , Bristol-Myers Squibb ( NYSE:BMY )
On Friday, 15 March, the FDA's Oncologic Drugs Advisory Committee will meet to discuss Johnson & Johnson JNJ / Legend Biotech Corporation's LEGN supplemental biologics license application for Carvykti ( ciltacabtagene autoleucel ) for relapsed or refractory multiple myeloma, who have received at ...
In Article Trend: Neutral
March 13, 2024 (15:30) / "Benzinga" (by Globe Newswire)
Chronic Myeloid Leukemia Treatment Market On A Growth Trajectory: Market Size To Reach $12 Billion By 2028 As Per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024
LONDON, March 13, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Chronic Myeloid Leukemia Treatment Global Market Report 2024, the chronic myeloid leukemia treatment market has witnessed robust growth in recent years, and projections indicate a continued upward trajectory.
In Article Trend: Somewhat-Bullish
March 13, 2024 (13:43) / "CNBC" (by Annika Kim Constantino)
Healthy Returns: What's next in the legal fight over Medicare drug price negotiations
The legal battle over Medicare drug price negotiations is so far looking favorable for the Biden administration. Meanwhile, CNBC is on the ground at HIMSS!
In Article Trend: Neutral
March 13, 2024 (12:18) / "Benzinga" (by Meg Flippin)
Nanotechnology's Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX's Nanotechnology - AstraZeneca ( NASDAQ:AZN ) , FendX Technologies ( OTC:FDXTF )
From therapeutics to new drug delivery systems, nanotechnology can play an important role in fighting infectious diseases. A prime example is evident in the development of the COVID-19 vaccines. During the pandemic, Pfizer Inc. PFE, Moderna Inc. MRNA, Johnson & Johnson JNJ, AstraZeneca Plc.
In Article Trend: Neutral
March 13, 2024 (12:00) / "Canada Newswire" (by Foot Locker)
FOOT LOCKER, INC. NAMES CINDY CARLISLE CHIEF HUMAN RESOURCES OFFICER
Carlisle brings over 24 years of leadership experience to her role at Foot Locker, Inc. NEW YORK, March 13, 2024 /CNW/ -- Foot Locker, Inc. ( NYSE: FL ) today announced that Cindy Carlisle has assumed the role of Executive Vice President and Chief Human Resources Officer.
In Article Trend: Somewhat-Bullish
March 13, 2024 (09:21) / "Motley Fool" (by Sean Williams)
3 No-Brainer Stocks to Buy With $300 Right Now
A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses.
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:30) / "GlobeNewswire" (by Chemometec A/S)
Appointment of new CEO
ANNOUNCEMENT NO. 255 ( Changed category - Inside information ...
In Article Trend: Somewhat-Bullish
March 13, 2024 (08:02) / "GlobeNewswire" (by Chemometec A/S)
March 13, 2024 (07:00) / "GlobeNewswire" (by Faron Pharmaceuticals Oy)
Faron's Financial Statement Release January 1 to December 31, 2023
TURKU, Finland and BOSTON, March 13, 2024 ( GLOBE NEWSWIRE ) -- Faron Pharmaceuticals Ltd. ( "Faron" or "the Company" ) ( AIM: FARN, First North: FARON ) , a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (19:05) / "Benzinga" (by Surbhi Jain)
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal - Johnson & Johnson ( NYSE:JNJ )
Johnson & Johnson JNJ stock hasn't displayed much momentum: it is down 1.22% over the past six months, up 5.57% over the past year and up 3% YTD. The stock recently made a Golden Cross on the charts, signaling a reversal in trend. Johnson & Johnson's recent acquisition of Ambrx Biopharma boosted ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (16:23) / "Benzinga" (by Globe Newswire)
CIO Leadership: The Call for Visionary Global Leadership Will Power the Discussion at HMG Strategy's 17th Annual New York CIO Summit of America on April 11
WESTPORT, Conn., March 12, 2024 ( GLOBE NEWSWIRE ) -- HMG Strategy, the World's #1 platform for enabling technology executives to reimagine the enterprise and reshape the business world, is thrilled to announce that its signature event - the 17th Annual New York CIO Summit of America - will be ...
In Article Trend: Somewhat-Bullish
March 12, 2024 (14:20) / "Benzinga" (by Globe Newswire)
Global Contraceptive Drugs Market Size is Projected to Reach USD 28.96 billion by 2030, Growing at a CAGR of 7.3%: Straits Research - Agile Therapeutics ( NASDAQ:AGRX ) , GSK ( NYSE:GSK )
New York, United States, March 12, 2024 ( GLOBE NEWSWIRE ) -- Contraception encompasses the use of drugs to prevent pregnancy, the transmission of sexually transmitted diseases ( STDs ) , the transmission of sexually transmitted infections ( STIs ) , family planning, and birth control.
In Article Trend: Somewhat-Bullish
March 12, 2024 (12:03) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why You Should Retain Medtronic ( MDT ) Stock for Now
Investors continue to be optimistic about Medtronic (MDT) on the strength of the Neurosurgery and Cardiovascular and Neurosurgery portfolios.
In Article Trend: Somewhat-Bullish
March 12, 2024 (10:53) / "Motley Fool" (by Cory Renauer)
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
These industry leaders boast advantages that could expand their bottom lines for decades.
In Article Trend: Somewhat-Bullish
March 12, 2024 (09:39) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Seeks Expanded Use of Tremfya for Ulcerative Colitis
Tremfya is an important drug in J&J's (JNJ) immunology drugs portfolio and a key driver of top-line growth.
In Article Trend: Somewhat-Bullish
March 11, 2024 (21:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Increases Despite Market Slip: Here's What You Need to Know
The latest trading day saw Johnson & Johnson (JNJ) settling at $161.23, representing a +1.07% change from its previous close.
In Article Trend: Somewhat-Bullish
March 11, 2024 (20:00) / "PR Newswire" (by Trez Inc)
U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It Opens Its Scaling Seed Round
U.S. 1st Latino Tech Payroll Startup Trez.co, Announces Advisory Board of Industry Giants and C-Suite Executives As It ... PR ...
In Article Trend: Bullish
March 11, 2024 (16:00) / "Benzinga" (by Benzinga Insights)
Insights Into Johnson & Johnson's Performance Versus Peers In Pharmaceuticals Sector - Johnson & Johnson ( NYSE:JNJ )
In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating Johnson & Johnson JNJ in relation to its major competitors in ...
In Article Trend: Somewhat-Bullish
March 11, 2024 (14:00) / "PR Newswire"
UM Named Ad Age A-List 2024 Media Agency of the Year - PR Newswire
UM Named Ad Age A-List 2024 Media Agency of the Year PR ...
In Article Trend: Bullish
March 11, 2024 (11:15) / "PR Newswire" (by Neptune Software)
Neptune Software: 'Environmental Supply Chains - You Don't Need to Sacrifice Profitability to Act Sustainably'
OSLO, Norway, March 11, 2024 /PRNewswire/ -- As the urgency to achieve net-zero carbon emissions by 2050 increases, it's more important than ever before that companies do their part to address growing environmental and climate concerns worldwide.
In Article Trend: Somewhat-Bullish
March 11, 2024 (09:35) / "Motley Fool" (by Justin Pope)
3 Dividend Kings of Healthcare Stocks to Buy Hand Over Fist in March
These are some of the best-performing stocks in what's arguably society's most important industry.
In Article Trend: Somewhat-Bullish
March 11, 2024 (09:30) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - BlackRock, Inc.
ANNOUNCEMENT NO. ...
In Article Trend: Somewhat-Bullish
March 9, 2024 (17:44) / "Forbes" (by Joshua Cohen)
Legal Challenges To IRA Drug Price Negotiations Face Skeptical Judges
A district court judge in New Jersey heard oral arguments this week with respect to claims brought forth by four pharmaceutical companies that the Inflation Reduction Act's drug price negotiation provision violates certain constitutional rights.
In Article Trend: Neutral
March 9, 2024 (17:00) / "PR Newswire" (by Johnson & Johnson)
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in ... PR ...
In Article Trend: Neutral
March 9, 2024 (15:05) / "Benzinga" (by Globe Newswire)
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology ( AAD ) Annual Meeting
INCHEON, Korea, March 09, 2024 ( GLOBE NEWSWIRE ) -- Samsung Bioepis Co., Ltd. presented two new study results for its immunology portfolio - SB5, a biosimilar to Humira1 ( adalimumab ) , and SB17, a proposed biosimilar to Stelara2 ( ustekinumab ) - at the 2024 American Academy of Dermatology ( ...
In Article Trend: Neutral
March 8, 2024 (19:01) / "Benzinga" (by Benzinga Insights)
Johnson & Johnson Unusual Options Activity For March 08 - Johnson & Johnson ( NYSE:JNJ )
Deep-pocketed investors have adopted a bearish approach towards Johnson & Johnson JNJ, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
In Article Trend: Somewhat-Bullish
March 8, 2024 (18:41) / "Barrons" (by Andrew Bary)
Retail Investors Could Make $2,000 on Cummins Exchange Offer. Here's How.
An exchange offer by Cummins , the diesel engine maker, for shares in Atmus Filtration Technologies allows small investors to fully participate and potentially make about $2,000 on the trade in the next week or so.
In Article Trend: Somewhat-Bullish
March 8, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Should You Invest in the VanEck Pharmaceutical ETF ( PPH ) ?
Sector ETF report for PPH ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:52) / "Benzinga" (by Vandana Singh)
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx ( NASDAQ:ACLX )
Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
In Article Trend: Somewhat-Bullish
March 7, 2024 (13:07) / "Canada Newswire" (by Noa Therapeutics)
Noa Therapeutics Secures Pre-Seed Financing to Transform the Treatment of Inflammatory Disease
TORONTO, March 7, 2024 /CNW/ - Noa Therapeutics, a preclinical stage biotech company with a portfolio of novel trimodal therapeutics to address inflammatory barrier diseases, announced that they have secured an oversubscribed pre-seed financing round.
In Article Trend: Neutral
March 7, 2024 (06:15) / "Barrons" (by Josh Nathan-Kazis)
Biden Will Tout Lower Drug Prices in State of the Union. Big Pharma Might Be Losing the Fight.
Big Pharma Is Running Out of Time to Block Medicare Drug Price Negotiations ...
In Article Trend: Neutral
March 6, 2024 (23:31) / "CNN" (by Jacqueline Howard)
Cancer-causing chemical can form at 'unacceptably high levels' in certain acne products, independent lab claims
High levels of benzene, a cancer-causing chemical, can form in acne treatment products containing benzoyl peroxide, according to a new report from Valisure, an independent laboratory.
In Article Trend: Neutral
March 6, 2024 (21:36) / "The Atlantic" (by Jacob Stern)
He Got 49 COVID Shots in One Month!
On June 3, 2021, a roughly 60-year-old man in the riverside city of Magdeburg, Germany, received his first COVID vaccine. He opted for Johnson & Johnson's shot, popular at that point because unlike Pfizer's and Moderna's vaccines, it was one-and-done. But that, evidently, was not what he had in ...
In Article Trend: Neutral
March 6, 2024 (18:20) / "Benzinga" (by Globe Newswire)
Ambrx Shareholders Approve Acquisition by Johnson & Johnson - Ambrx Biopharma ( NASDAQ:AMAM )
SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( "Ambrx" or the "Company" ) AMAM, today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of Shareholders.
In Article Trend: Somewhat-Bullish
March 6, 2024 (18:20) / "GlobeNewswire" (by Ambrx Biopharma Inc.)
Ambrx Shareholders Approve Acquisition by Johnson & Johnson
SAN DIEGO, March 06, 2024 ( GLOBE NEWSWIRE ) -- Ambrx Biopharma, Inc., ( "Ambrx" or the "Company" ) ( NASDAQ: AMAM ) , today announced that its shareholders approved a proposal to adopt the merger agreement entered into between the Company and Johnson & Johnson at its Special Meeting of ...
In Article Trend: Somewhat-Bullish
March 6, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Encephalitis Treatment Market Overview 2024-2028: Expected Market Size, Major Growth Factors And Lucrative Segments As Per The Business Research Company's Encephalitis Treatment Global Market Report 2024
LONDON, March 06, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's encephalitis treatment global market report 2024, the encephalitis treatment market has exhibited robust growth in recent years, with a notable increase in market size.
In Article Trend: Somewhat-Bullish
)
March 6, 2024 (16:15) / "Business Standard" (by Bloomberg)
Chemical linked to cancer found in acne treatment creams including Proactiv | World News
Chemical linked to cancer found in acne treatment creams including Proactiv Business Standard ...
In Article Trend: Neutral
March 6, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Is a Trending Stock: Facts to Know Before Betting on It
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In Article Trend: Somewhat-Bullish
March 6, 2024 (11:11) / "CNN" (by Mira Cheng)
A man deliberately got 217 Covid shots. Here's what happened
One German man has redefined "man on a mission." A 62-year-old from Magdeburg deliberately got 217 Covid-19 vaccine shots in the span of 29 months, according to a new study, going against national vaccine recommendations. That's an average of one jab every four days.
In Article Trend: Neutral
March 5, 2024 (21:45) / "Benzinga" (by Natan Ponieman)
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic - AstraZeneca ( NASDAQ:AZN ) , Bristol-Myers Squibb ( NYSE:BMY )
As President Joe Biden prepares for his State of the Union address on Thursday, he's expected to touch on several key issues including Bidenomics, access to healthcare and the U.S.' role in the world.
In Article Trend: Neutral
March 5, 2024 (18:17) / "Benzinga" (by Benzinga Insights)
Smart Money Is Betting Big In JNJ Options - Johnson & Johnson ( NYSE:JNJ )
Financial giants have made a conspicuous bullish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson JNJ revealed 12 unusual trades. Delving into the details, we found 75% of traders were bullish, while 25% showed bearish tendencies.
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:00) / "PR Newswire" (by LLC)
BDA Receives Best Place to Work Recognition by The Sports Business Journal
Global Merchandising Agency Earns Medalist Honors for Outstanding Leadership and Commitment to Employee Satisfaction
In Article Trend: Bullish
March 5, 2024 (11:01) / "GlobeNewswire" (by Chemometec A/S)
Major shareholder announcement - AIM International Mutual Funds
ANNOUNCEMENT NO. ...
In Article Trend: Neutral
March 5, 2024 (11:00) / "GlobeNewswire" (by Chemometec A/S)
March 5, 2024 (07:34) / "Money Control"
Big businesses hit with management idea drought
The multibillion-dollar industry has lost the intellectual momentum and edge. There are only so many ideas that you can have about managing people or resources, and many of the best were generated long ago ...
In Article Trend: Neutral
March 5, 2024 (06:00) / "GlobeNewswire" (by Sandoz International GmbH)
Sandoz announces nominations to the Board of Directors and leadership change
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (06:00) / "Business Insider" (by markets.businessinsider.com)
Sandoz announces nominations to the Board of Directors and leadership change
• Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting • Remco Steenbergen appointed as Sandoz CFO and member of Executive Committee as of July 1, 2024, and consequently not standing for re-election to Board of ...
In Article Trend: Somewhat-Bullish
March 5, 2024 (06:00) / "Benzinga" (by Globe Newswire)
Sandoz announces nominations to the Board of Directors and leadership change - Sandoz Group ( OTC:SDZNY )
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Mathai Mammen and Michael Rechsteiner nominated to stand for election to Sandoz Board of Directors at upcoming Annual General Meeting
In Article Trend: Somewhat-Bullish
March 4, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Dips More Than Broader Market: What You Should Know
Johnson & Johnson (JNJ) closed the most recent trading day at $159.84, moving -1.41% from the previous trading session.
In Article Trend: Neutral
March 4, 2024 (16:51) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) Secures Full FDA Nod for Rybrevant in Lung Cancer
The approval is based on data from a late-stage study wherein treatment with J&J's (JNJ) Rybrevant plus chemotherapy reduced the disease-progression risk or death by 61% in certain NSCLC patients.
In Article Trend: Somewhat-Bullish
March 4, 2024 (13:05) / "Benzinga" (by Globe Newswire)
Global Urinary Incontinence Treatment Devices Market Size is Estimated to Reach USD 6.02 billion by 2030, Growing at a CAGR of 6.58%: Straits Research
New York, United States, March 04, 2024 ( GLOBE NEWSWIRE ) -- A medical disease called urinary incontinence causes uncontrollable urine loss. Medical devices are used to treat chronic urine incontinence and to grow and strengthen the pelvic floor muscles.
In Article Trend: Neutral
March 4, 2024 (12:00) / "Benzinga" (by Globe Newswire)
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors - Immunome ( NASDAQ:IMNM ) , Shattuck Labs ( NASDAQ:STTK )
AUSTIN, TX and DURHAM, NC, March 04, 2024 ( GLOBE NEWSWIRE ) -- Shattuck Labs, Inc. ( Shattuck ) STTK, a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune ...
In Article Trend: Somewhat-Bullish
March 3, 2024 (15:01) / "MarketWatch" (by Bill Peters)
Dow companies made bigger-than-normal adjustments to profits in Q4
The median difference between per-share profit reported based on generally accepted accounting principles and the adjusted kind stood at 31%.
In Article Trend: Neutral
March 3, 2024 (13:14) / "Motley Fool" (by David Jagielski)
Will Johnson & Johnson Be a Trillion-Dollar Stock by 2030?
Can Johnson & Johnson stock become a hot buy for growth-focused investors, or is this mainly just a dividend play?
In Article Trend: Somewhat-Bullish
March 3, 2024 (11:55) / "Motley Fool" (by James Brumley)
3 Nuggets of Investing Wisdom From Warren Buffett's Latest Letter to Berkshire Hathaway Shareholders
The Oracle of Omaha is still as good at explaining how he picks stocks as he is at actually picking them.
In Article Trend: Neutral
March 2, 2024 (11:30) / "Forbes" (by John Dobosz)
Berkshire Hathaway Has $168 Billion In Cash: These Stocks Should Be On Buffett's Buy List
Based on what Warren Buffett says and what he owns, it would not be surprising to see Berkshire buy stakes in these 13 stocks.
In Article Trend: Somewhat-Bullish
March 2, 2024 (02:32) / "PR Newswire"
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... - PR Newswire
Mezzion Pharmaceuticals Announces Dr. Rahul Rathod of Boston Children's Hospital and Harvard Medical School as ... PR ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (20:59) / "PR Newswire" (by Johnson & Johnson)
RYBREVANT® ( amivantamab-vmjw ) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
RYBREVANT® ( amivantamab-vmjw ) in Combination With Chemotherapy Is the First FDA Approved Therapy for First ... PR ...
In Article Trend: Neutral
March 1, 2024 (19:26) / "Canada Newswire" (by JAMP Pharma)
JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of Stelara® ( ustekinumab ) in Canada
JAMP Pharma Group announces the commercial launch and product availability for PrJamteki™, the first biosimilar of ... Canada ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (19:02) / "CNBC" (by Annika Kim Constantino)
Judge rejects AstraZeneca's challenge to Medicare drug price negotiations
U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.
In Article Trend: Neutral
March 1, 2024 (14:27) / "Barrons" (by Avi Salzman)
This Firm Supplies Clean Power to AI Tech Companies. The CEO Wants More Credit.
AES Has an AI Edge. The CEO Wants More Credit. ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (11:20) / "Zacks Commentary" (by Zacks Equity Research)
Is WisdomTree U.S. Quality Dividend Growth ETF ( DGRW ) a Strong ETF Right Now?
Smart Beta ETF report for ...
In Article Trend: Somewhat-Bullish
March 1, 2024 (04:12) / "Money Control"
Biocon shares gain on licence deal with Janssen, J&J for US markets
Biocon Share Price | In an another development, the company's subsidiary received observations from US Food and Drug Administration ( USFDA ) .
In Article Trend: Somewhat-Bullish
)
March 1, 2024 (02:08) / "Business Standard" (by Harshita Singh)
Stocks to watch today, March 01: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T | | News on Markets
Stocks to watch: Paytm, Tata Group, Airtel, Biocon, Suven, Vedanta, L&T Business Standard ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (17:14) / "CNBC" (by Jim Cramer)
We're trimming an embattled portfolio stock facing a binary event that could go either way
The sale involves roughly one-quarter of our position to manage our downside risk ahead of a key court ruling.
In Article Trend: Neutral
February 29, 2024 (16:30) / "Zacks Commentary" (by Zacks Equity Research)
Pfizer ( PFE ) Down 0.2% Since Last Earnings Report: Can It Rebound?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
February 29, 2024 (16:30) / "Benzinga" (by Globe Newswire)
Urinary Tract Cancer Market To Grow At A CAGR Of More Than 19% With The Rising Prevalence Of Urinary Tract Infections As Per The Business Research Company's Urinary Tract Cancer Global Market Report 2024
LONDON, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's urinary tract cancer global market report 2024, the urinary tract cancer market has experienced remarkable growth in recent years, surging from $2.65 billion in 2023 to $3.21 billion in 2024, representing a ...
In Article Trend: Neutral
February 29, 2024 (15:35) / "Benzinga" (by Globe Newswire)
Global Onychomycosis Treatment Market Size is Estimated to Reach USD 4.51 Billion by 2030, Growing at a CAGR of 5.61%: Straits Research
New York, United States, Feb. 29, 2024 ( GLOBE NEWSWIRE ) -- Onychomycosis is a fungal condition that affects the fingernails and toenails and can be painful, ugly, and persistent. Several types of onychomycosis include proximal subungual, white superficial, and distal subungual.
In Article Trend: Neutral
)
February 29, 2024 (14:52) / "Business Standard" (by Aneeka Chatterjee)
Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug | Company News
Biocon Biologics signs agreement with Janssen Biotech for psoriasis drug Business Standard ...
In Article Trend: Bullish
February 29, 2024 (13:00) / "CNBC" (by Annika Kim Constantino)
Pfizer RSV vaccine maintains protection in older adults over two seasons in trial
The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.
In Article Trend: Neutral
February 29, 2024 (10:06) / "Motley Fool" (by Sean Williams)
Want $1,000 in Ultra-Safe Annual Dividend Income? Invest $19,000 Into the Following 3 Time-Tested Dividend Kings.
These rock-solid dividend stocks, which sport an average yield of 5.26%, have raised their base annual payouts for between 54 and 62 consecutive years.
In Article Trend: Somewhat-Bullish
February 28, 2024 (22:00) / "Canada Newswire" (by DRI Healthcare Trust)
DRI Healthcare Trust Reports Fourth Quarter and Fiscal 2023 Results
- 82% royalty income growth over prior year period underscores transformative year - - Announcing 2024 royalty income guidance of US$153 to US$155 million, excluding milestone income and any new transactions - - Increasing quarterly cash distribution -
In Article Trend: Somewhat-Bullish
February 28, 2024 (15:18) / "Benzinga" (by PRNewswire)
Alexander Kalchev and Paul Ducré appointed CEOs of DDB Paris - Omnicom Group ( NYSE:OMC )
A story of friendship and a natural transition PARIS, Feb. 28, 2024 /PRNewswire/ -- DDB Paris announces the elevation of globally acclaimed CCO Alexander Kalchev and Paul Ducré as new CEOs, together assuming the role of current CEO Jean-Luc Bravi who will become Chairman, DDB France.
In Article Trend: Bullish
February 28, 2024 (12:00) / "GlobeNewswire" (by Inc.)
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
CAMBRIDGE, Mass., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Mersana Therapeutics, Inc. ( NASDAQ: MRSN ) , a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( ADCs ) targeting cancers in areas of high unmet medical need, today ...
In Article Trend: Neutral
February 28, 2024 (10:49) / "Motley Fool" (by Alex Carchidi)
Johnson & Johnson Stock Has 33% Upside, According to 1 Wall Street Analyst
Management's thesis regarding the spinoff is now being tested.
In Article Trend: Somewhat-Bullish
February 28, 2024 (10:44) / "Motley Fool" (by Justin Pope)
Nearing Retirement? These Stocks Are as Cautious as They Come
Healthcare blue chips can provide retirees the consistency they need while growing their nest eggs further.
In Article Trend: Somewhat-Bullish
February 28, 2024 (10:02) / "Benzinga" (by Globe Newswire)
Intracranial Stents Market Projected to Achieve USD 3.4 billion by 2031, with a 5.2% CAGR Growth: Transparency Market Research, Inc.
Wilmington, Delaware, United States, Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Transparency Market Research Inc. - The global intracranial stents market is projected to grow at a CAGR of 5.2% from 2023 to 2031. As per the report published by TMR, a valuation of US$ 3.4 billion is anticipated for the ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (22:45) / "Zacks Commentary" (by Zacks Equity Research)
Johnson & Johnson ( JNJ ) Rises But Trails Market: What Investors Should Know
Johnson & Johnson (JNJ) concluded the recent trading session at $160.98, signifying a +0.12% move from its prior day's close.
In Article Trend: Neutral
February 27, 2024 (17:21) / "Zacks Commentary" (by Zacks Equity Research)
Here's Why Investors Should Retain STERIS ( STE ) Stock for Now
Investors are optimistic about STERIS (STE) on continuous recovery of healthcare procedures and upbeat 2024 guidance.
In Article Trend: Somewhat-Bullish
February 27, 2024 (14:00) / "PR Newswire" (by The Josh Bersin Company)
The Josh Bersin Company Announces New Offerings to Accelerate HR's Transition to AI
• New Josh Bersin Academy Certificate Program and in-depth playbooks and case studies • New AI offering Galileo™ available for HR problem solving and education • New AI experts to keynote Josh Bersin Company "Irresistible" future of work conference
In Article Trend: Somewhat-Bullish
February 27, 2024 (12:45) / "GlobeNewswire" (by The Greater Cannabis Company)
GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy
BALTIMORE, MD, Feb. 27, 2024 ( GLOBE NEWSWIRE ) -- Greater Cannabis Company, Inc. ( "GCANRx" or the "Company" ) ( OTC: GCAN ) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has completed the preclinical ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (12:00) / "Forbes" (by Trefis Team)
Should You Pick Johnson & Johnson Stock At $160?
Johnson & Johnson ( NYSE: JNJ ) reported its Q4 results last month, with revenues and earnings marginally above the street estimates. The company reported revenue of $21.4 billion and adjusted earnings of $2.29 per share, compared to the consensus estimates of $21.0 billion and $2.28, ...
In Article Trend: Somewhat-Bullish
February 27, 2024 (12:00) / "PR Newswire" (by Nested Therapeutics Inc.)
Nested Therapeutics Strengthens Board of Directors with Appointment of New Chair and Directors
CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today announced the appointment of three members to its board of directors: John A.
In Article Trend: Neutral
February 27, 2024 (11:55) / "Zacks Commentary" (by Zacks Equity Research)
2 Boston Partners Mutual Funds for Steady Returns
Invest in Boston Partners mutual funds like BPRRX and BPAVX for consistent returns.
In Article Trend: Somewhat-Bullish
February 27, 2024 (01:15) / "PR Newswire" (by Research and Markets)
Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework Implementation
Pharmaceutical Industry Research Highlights Sustainability and Growth Opportunities Through 6P Framework ... PR ...
In Article Trend: Bullish
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website